Podcasts about Newcastle University

Vous pensez ne plus avoir besoin de vitamine D dès que les beaux jours reviennent ? C'est aussi ce que je pensais : j'avais arrêté ma supplémentation en juin, rassuré par mes bons niveaux du printemps. Puis une discussion avec ma nutritionniste et une étude qui a fait du bruit ont semé le doute. Dans cet épisode, je décortique ce que disent vraiment les études sur la synthèse de la vitamine D et je vous donne les clés pour savoir si votre mode de vie remplit réellement les conditions pour en fabriquer suffisamment, même en plein été.Liens complémentairesGratuit : Le kit Reboot pour retrouver la forme et l'énergie avec la méthode SAMi et des outils : https://sn.soulier.xyz/kitLe Protocole Perte de Gras : https://go.soulier.xyz/protocolesnLa Stratégie FlowFit pour bouger et plus et prendre du muscle (tarif de lancement spécial) : https://go.soulier.xyz/flowfitsnComposez vos salades protéinées en quelques secondes avec l'assistant Salade Express : https://go.soulier.xyz/saladesnTous les liens complémentaires et anciens épisodes : https://sn.soulier.xyz/191Nutripure : https://go.soulier.xyz/NutripureSN. Profitez de 10% de réduction sur votre première commande avec le code HAMSTERSRejoindre le Hamsters Running Club : https://sn.soulier.xyz/hrcEn mars, mes analyses de sang montraient des niveaux de vitamine D très corrects. C'était le résultat de la combinaison d'une bonne alimentation, de sorties régulières et d'une supplémentation hivernale. Logiquement, avec l'arrivée des beaux jours, j'ai arrêté ma cure : plus de soleil, plus de luminosité, donc plus besoin, non ?C'est ce que beaucoup d'entre nous pensent. Mais une conversation avec ma nutritionniste m'a fait douter, et une étude récente de la Newcastle University (publiée en juin 2026 dans l'European Journal of Clinical Nutrition) est venue confirmer ce doute : chez les participants suivis, les niveaux de vitamine D ne remontaient pas l'été, alors même que la logique voudrait l'inverse.Avant de généraliser, j'ai voulu vérifier les biais possibles de cette étude (financement, population étudiée, latitude) et surtout comprendre ce que la science dit vraiment des conditions de synthèse cutanée de la vitamine D : quelle heure de la journée compte, quelle surface de peau exposée, quel rôle joue la crème solaire, l'âge, ou un mode de vie sédentaire.En confrontant ces données à mon propre mode de vie (sorties matinales, travail de bureau, peu d'exposition en milieu de journée) j'ai eu une vraie surprise sur ma propre situation.Cet épisode n'est pas un raccourci du type "prenez de la vitamine D toute l'année" : c'est une invitation à interroger vos propres habitudes d'exposition au soleil, pour savoir si vous remplissez réellement les conditions pour en synthétiser assez ou si, comme moi, l'été ne change pas grand-chose.Dans cet épisode :Faut-il vraiment arrêter la vitamine D dès que l'été arrive ?Que révèle une étude récente de la Newcastle University sur les niveaux de vitamine D en été ?Quels sont les biais possibles de cette étude à connaître avant d'en tirer des conclusions ?Comment la peau synthétise-t-elle réellement la vitamine D grâce au soleil ?La crème solaire bloque-t-elle vraiment la synthèse de vitamine D ?Quelle heure de la journée est la plus efficace pour synthétiser de la vitamine D ?Quel rôle joue l'âge dans la capacité à produire de la vitamine D ?Un mode de vie sédentaire ou des sorties sportives matinales peuvent-ils suffire à limiter la synthèse malgré le soleil d'été ?Nouveau : Le protocole Perte de Gras 2025 ❤️ Me suivre Tous les liens sont ici

In this episode of The Dairy Podcast Show, Holly Malins, Ruminant Business Manager at Evonik Animal Nutrition, explains how capsaicin compounds from chili peppers can support dairy cow performance. She explores its effects on digestion, nutrient absorption, and glucose use, especially during early lactation and heat stress. Get practical insights that highlight consistency, application, and production responses. Listen now on all major platforms!"Capsaicinoids act as bioactive compounds that influence digestion and metabolism through receptor activation within the gastrointestinal tract."Meet the guest: Holly Malins earned a degree in Agriculture from Newcastle University and a Master's in Applied Poultry Science from the University of Glasgow. At Evonik Animal Nutrition, she focuses on ruminant nutrition, emphasizing amino acids and innovative feed solutions to improve dairy cow performance across Europe. Learn more about capsaicin strategies with Holly Malins on The Dairy Podcast Show, available on all major platforms.Liked this one? Don't stop now — Here's what we think you'll love!Tales Lelis: Rumen-Protected Amino Acids | Ep. 70What you'll learn:(00:00) Highlight(01:36) Introduction(04:43) Guest background overview(06:59) Capsaicinoids explained(12:36) Capsaicin function(17:56) Farm applications(24:09) Capsaicin sources availability(24:53) Final questionsThe Dairy Podcast Show is trusted and supported by innovative companies like:* Evonik* Adisseo* CowManager* Afimilk* Agri-Comfort- DietForge- AHV- BoviSync- Natural Biologics- dsm-firmenich- Protekta- Agrarian Solutions- Chemlock Nutrition- Rangen Group

This lecture will focus on independently produced Chinese documentary cinema as it has entered the Anglophone industry market. Using “Plastic China” by the award-winning director Wang Jiuliang as a case study, I will explore what the implications of cross-border collaborations are for documentary form and content, and how this may encourage a particular set of viewer responses. This will allow me to locate the documentary form in relation to broader liberal arguments over China's place in the world system and assess the limitations of this approach to “going global” for independent Chinese documentary.This lecture was recorded by Luke Robinson on the 27th of May 2026Luke Robinson is a Senior Lecturer/Associate Professor in Film Studies in the Faculty of Media, Arts, and Humanitiies, University of Sussex.He is the author of Independent Chinese Documentary: From the Studio to the Street, and the co-editor of two further collections on Chinese film culture: (with Chris Berry) Chinese Film Festivals: Sites of Translation and (with Chris Berry, Lydia Wu and Sabrina Yu) Chinese Independent Cinema: Past, Present, and a Questionable Future.His writing has appeared in books and journals including DV-made China, The New Chinese Documentary Movement, Vocal Projections, Screening China's Soft Power, positions: Asia cultures critique, Film Studies, Screen, and Journal of Chinese Cinemas.Between 2019 and 2025 he was co-investigator on the AHRC-funded project, “Independent Cinema in China: State, Market, and Film Culture”. One of the outcomes of this grant was the establishment of the Chinese Independent Film Archive, located at Newcastle University.The transcript of the lecture is available from the Gresham College website: https://www.gresham.ac.uk/watch-now/chinese-documentaryGresham College has offered free public lectures for over 400 years, thanks to the generosity of our supporters. There are currently over 2,500 lectures free to access. We believe that everyone should have the opportunity to learn from some of the greatest minds. To support Gresham College's mission, please consider making a donation: https://www.gresham.ac.uk/get-involved/support-us/make-donation/donate-today Website:  https://gresham.ac.ukX: https://x.com/GreshamCollegeFacebook: https://facebook.com/greshamcollegeInstagram: https://instagram.com/greshamcollegeBluesky: https://bsky.app/profile/greshamcollege.bsky.social TikTok: https://www.tiktok.com/@greshamcollegeSupport Us: https://www.gresham.ac.uk/get-involved/support-us/make-donation/donate-todaySupport the show

What will a Burnham premiership mean for Wales? Former Labour communications advisor Scarlett MccGwire discusses. With a new party in government, what is the future of transport in Wales? Cardiff University's Mark Barry and the new deputy minister for transport, Mark Hooper are in the studio. We've had the hottest June on record and climate change is getting the blame. Professor Hayley Fowler from Newcastle University tells us why. And it's the 150th anniversary of the battle of Little Big Horn in Montana, USA. Journalist and author Mike Lewis knows about a Welsh connection.Our interviews with new members of the Senedd continue: this week we have one of Plaid Cymru's three Rhondda Cynon Merthyr MSs, Sara Crowley.

Dr. Martin Farr, a senior lecturer in contemporary British history at Newcastle University, joined "Forbes Newsroom" to discuss Prime Minister Keir Starmer's resignation and the impact that his stepping down could have on politics in the United Kingdom. Learn more about your ad choices. Visit megaphone.fm/adchoices

A daily low dose of aspirin could significantly reduce the risk of bowel cancer in people with Lynch syndrome, an inherited condition that increases the likelihood of developing certain cancers.   In this episode, we explore the findings from the landmark CaPP3 trial, hear from a participant living with Lynch syndrome, and discuss how genomics could help shift healthcare from treatment to prevention.  Our host, Sharon Jones is joined by:  Dr Katie Snape, Principal Clinician for Population Health at Genomics England  Professor Sir John Burn, Professor of Clinical Genetics at Newcastle University  Drew Hyde, participant in the Cancer Prevention Programme (CaPP3)  Links:  Listen to: How can genomics help us understand cancer?  "I think knowing is always a good thing. And obviously, I wish I'd known earlier, and then, I could have taken more measures earlier on. So I think knowledge is definitely a good thing. And it would be great if more people could be tested or could find out if they were carriers at an early age, I think."  You can download the transcript or read it below. [00:00:00] Sharon: Welcome to Behind the Genes. In today's episode, we'll explore the research which shows how a low dose of aspirin can halve the risk of bowel cancer in people with Lynch syndrome. We'll hear about the real-life impact of living with the condition, and look at how genomics can help shape a more preventative approach to care in the future. [00:00:20] I'm Sharon Jones, and to help us unpack all of that, I'm joined by our guests, Dr. Katie Snape, principal clinician for population health at Genomics England; Sir John Burn, professor of clinical genetics at Newcastle University; and Drew Hyde, a participant in the Cancer Prevention Programme, which is also known as the CaPP3 trial. [00:00:42] So to start with the basics, Katie, can you walk us through what cancer is in simple terms? [00:00:50] Katie: Sure, Sharon. So, our body is made up of cells. Those are the building blocks that, that make us as humans and other creatures and plants. And our cells need to keep dividing throughout our lifetime as our bodies are growing and working normally. [00:01:06] And so we need to have processes in place in our body where our cells can divide, but then also stop dividing when we don't need them to carry on dividing. What happens in a cancer cell is basically that cell becomes abnormal, and it doesn't follow the normal checks and balances and rules of cell division. [00:01:23] So it starts to divide and grow uncontrollably, and it can start to invade other tissues and obviously, that can cause serious consequences. [00:01:33] Sharon: We'll hear a lot more from Dr. Katie Snape in this episode. But before we move on, I just wanted to flag that there was an episode of our Genomics 101 explainer series with Katie dedicated to helping us get to grips with how genomics can help us understand and diagnose cancer. [00:01:47] Do go and check that out. We'll put a link to that in the episode description. [00:01:54] So the World Health Organization estimates between 30 to 50% of all cancers are preventable. So, Katie, when we talk about cancer being preventable, what does that actually mean? And what's an example of cancer prevention that people might already know? [00:02:11] Katie: Yeah. So some cancers are due to chance or just mistakes happening as our cells copy. [00:02:19] Other cancers are because there has been damage to the genetic information within the cell that can be caused by certain things that can cause damage to DNA. So for example, a sort of obvious answer would be skin cancer. Skin cancers can be caused by sunlight, the, the UV light in the sun, and particularly if we burn our skin or, or get sun damage to our skin, increases the chance of us developing a skin cancer. [00:02:44] So you can think of lots of other examples such as cigarette smoking and lung cancer, and so we know that there are a number of different risk factors that increase the chance of our cells developing damage and becoming abnormal cells and growing uncontrollably. So when we talk about prevention, we might think, well, could we reduce some of those risk factors and therefore reduce the chance of those cells getting damaged and becoming cancer cells? [00:03:10] So I gave the example of skin cancer. We might put sun cream on if we're going out in the midday sun, for example. That reduces the damage of the UV light onto our skin cells. Or we might help people to go into a smoking prevention programme or, you know, other risk factors, such as we know that being very overweight can increase the chance of cancer. [00:03:31] We might help people get into more exercise regimes or improve people's diets. So those are the sorts of things that we might do sort of for environmental risk factors. But we also know, particularly in this context, that sometimes people are born, they carry genetic changes within their cells that they're born with, that are inherited, that run through families, and those can also increase the chance of some cancers developing. [00:03:56] And for those people at higher genetic risk, then we might look to other ways that we might reduce that risk. We can't change the genetic changes in their cells, but we might be able to put things in place to reduce the risk for those individuals, and that might be medication, it might be surgery, or there could be other things that we might be able to offer. [00:04:15] Sharon: Yeah, and with that in mind, is there anything more, you know, that you can share about some of those risk factors that someone is more likely to develop cancer? [00:04:25] Katie: Yeah. So actually, the, the biggest risk factor for developing cancer is age. The older we get, the more times our cells have divided, the more chance there is of a copying mistake that, that, that can cause that cell to become abnormal and start growing uncontrollably. [00:04:41] And that's why cancer becomes more common the older we get. We obviously can't change our aging process. Then, as I've said, sometimes we're born with certain specific inherited factors that increase the risk. That might be one big high-risk genetic factor, such as having a cancer gene that's important for, for that process of cell division that isn't working properly. [00:05:04] Or it could be that we have multiple lower genetic risk factors that can kind of add up together to increase the risk. And those often interplay with some of those environmental factors that we've talked about, like smoking, for example, or weight, or alcohol or other things like that. So most cancers are due to aging, and then there's a sort of interplay of genetic factors, but environmental factors as well. [00:05:30] Sharon: That's really interesting to understand. And the focus of this podcast is sort of looking at kind of Lynch syndrome and what findings have come out around aspirin and having a low dose of aspirin. So I want to kind of explore what Lynch syndrome is and, and then bring in Drew to talk about his experience of having Lynch syndrome and how he got involved in the trials themselves. [00:05:49] So from what I understand, Lynch syndrome is a genetic condition that can make some people more likely to have the chances of developing into bowel cancer. And Drew, this is your opportunity to sort of talk about what that's been like living with Lynch syndrome. And, you know, I'd like to understand more about your story and how it came about that you discovered that you had Lynch syndrome, and to share with our listeners your journey. [00:06:13] Drew: Yep. So in my case, I discovered I had the colon cancer before I discovered I was a Lynch syndrome carrier Basically, at the age of 50, I noticed some change in my health. You know, I was becoming a little bit more tired. My bowel movements had changed or whatever. So, I went to the GP and the GP basically said, "Well, you're probably too young for cancer, so let's look at other alternatives." [00:06:37] And I had blood tests and I had low iron, so I was on iron tablets for three months and whatever. Then eventually I went back and finally the GP said, "Well, let's try a colonoscopy." And the colonoscopy revealed that I did actually have colon cancer. And then very quickly I had surgery and, uh, then following that, I kind of asked the question, "Well, why me?" [00:06:59] You know, I'm only 50, 51. Yeah. You know, why me? [00:07:02] Drew: And basically, I was told, "Well, it's probably genetics." And then I was referred to, you know, St George's and Katie and I had the test and discovered that I was actually a Lynch syndrome carrier, and that's why, you know, I'd got the colon cancer at the age of 50, so. [00:07:17] Sharon: I mean, that's quite a journey. I mean, how did you feel when you're already on one pathway and then having to kind of find out more, you know, what was your experiences? What was the impact on your life? How did you, how did you feel? [00:07:27] Drew: I think I was lucky in that I had a very good surgeon. I had surgery very quickly, so that was the first hurdle. [00:07:32] Then I had to go on to chemotherapy, and the chemotherapy obviously is far worse than any surgery or anything else that comes before or after. But having got through that, then I went through the St George's onto the Lynch syndrome system. So, the most important thing then really was to basically identify what that meant for me, but also because it was an inherited characteristic, what it meant for my family. [00:07:57] One thing that was interesting, and I say, you know, the, the GP was saying, "Well, you're too young to have cancer," is that there wasn't any history of cancer in my family, you know, looking at older relatives. So, you know, to be fair to the GP, that wasn't an obvious marker. So basically, yeah, it was let's, you know, find out what it means now going forward. [00:08:21] Sharon: So, can you just take us back to when you were diagnosed with Lynch syndrome? What sort of guidance were you given at the time about managing your cancer risk? [00:08:30] Drew: Well, following the surgery, I was given various statistics which were fairly grim on what your percentage survival rate were in three years, five years, 10 years based on the surgery, whatever. [00:08:39] And that was kind of a bit harrowing. But, you know, assuming I'd get through five years, I felt it was, my chances were quite good. As for myself living with, living with Lynch syndrome, that, you know, I was aware that having had the colon cancer, I then had increased risk of other cancers. So since then, I've been on a screening programme, and I have colonoscopies or gastroscopies every year or two years. [00:09:04] So that's been very good. So, I believe now that if any other cancers were to appear, I would probably know very early on because they would be detected through a screening process before they got to a point where they would be, you know, maybe too difficult to resolve, so. So that's-- I think the screening programme, has been very, very good. [00:09:23] The main issue for me was what it meant for my family, being a genetic thing. So very quickly, my children, who were teenagers at the time, were both tested, and they went through some counselling with Katie beforehand, you know, about what it would mean for them to get a positive or negative result. [00:09:42] Unfortunately, my daughter was tested as negative, but my son was tested as positive, so he's now on the same cancer screening programme, and has colonoscopies every two years. So yeah. The mystery really, though, is where I inherited it from because my father died when I was very young. My mother was in a care home at the time, and I wanted to get her tested. [00:10:07] And at the time, her GP wouldn't test her on the basis that she was unable to give consent. But fortunately, I had power of attorney, and we could persuade him to do the test. But she tested negative. So I'm assuming I inherited it from my father's side. But most of my grandparents on that side of the family lived into their nineties without any apparent cancers. [00:10:32] So it's still a bit of a mystery how I inherited it, but what was important for me was to know which side of the family I'd inherited it from because obviously with cousins and whatever on different sides of the family, I wanted to be able to tell them what the situation was. My brother also tested negative, which was a positive. [00:10:54] So at the moment, it's just my son and I that have the defective gene. [00:10:59] Sharon: I'm sorry to hear that about your son, but does it- [00:11:01] Drew: Well, well, I mean, he, you know, he has to go through a colonoscopy every couple of years, which, you know, obviously is not a pleasant experience. But at least he knows that, you know, the first sign of any problem, the medics will be aware of it, and he'll be able to react. [00:11:16] Sharon: Has it changed your outlook on life, having this window in possibly knowing stuff or not knowing stuff? How has that affected you and, and your son as well? [00:11:25] Drew: I think knowing is always a good thing. And obviously, I wish I'd known earlier, and then, I could have taken more measures earlier on. So, I think knowledge is definitely a good thing. And it would be great if more people could be tested or could find out if they were carriers at an early age, I think. [00:11:42] Sharon: Yeah. That is really important. And moving into about the trial more broadly, scientists have known that there's been a link between cancer and aspirin for some time, with fewer cancers observed in people who take aspirin. So coming to you, John, could you share a bit more about the history of inherited cancer research and how the focus of Lynch Syndrome came about? [00:12:02] Because this isn't new, is it? [00:12:06] John: No, absolutely, Sharon. And in fact, this story, my story in this space begins 40 years ago when I was one of the geneticists who set out to try and find the genes that we've just been talking about. At that time, the group of patients who were the most obvious to begin with were young people with a condition called familial adenomatous polyposis, or FAP for short. [00:12:26] And they'd get thousands of polyps in their bowel, and the only way to treat that was to actually remove the whole bowel when they reached adulthood, which is a fairly extreme intervention. And I was running, I was setting up a registry. We were trying to find the gene at that time, and we'd just found it, in fact, but we also were trying to find all the families. [00:12:44] And I'd taken over responsibility for all the genetic services in the north of England, in the North East and Cumbria. And we'd, I'd started identifying families with FAP, and we went to visit one of those families, and this was the kind of light bulb moment for me because I walked into the room and mum had had her colon removed, and her son, Jonathan, had just had his first colonoscopy at the age of 12, and it was clear. [00:13:07] And I was about to give them the good news, but as I walked in, I noticed that he had little bumps on his forehead called osteomas, little bony bumps. His mother had them just the same, and it was one of the features of this condition. So I knew he had the gene even though he hadn't yet got the polyps. [00:13:21] Sharon: Wow. [00:13:22] John: And it made me think, wouldn't it be nice if we could do something to prevent these things happening rather than just waiting for an operation? And as it happened at the time, I was leading the English end of a big study, which you'll probably be aware of, which we're, we're, we were doing the vitamin study on women with spina bifida babies, and we were just about to identify folic acid as a way of preventing spina bifida in pregnant women. [00:13:45] So I had these two thoughts in my head. Maybe we could set up a trial like this folic acid trial, and then one of my friends in Edinburgh said, 'Have you seen this paper from Melbourne?' Gabriel Kuhn had just done a big study looking at people with colon cancer. It seemed that people who took a lot of aspirin didn't seem to get as much bowel cancer in Melbourne as those who didn't. So that was the design set up. [00:14:08] We were applying to Europe for a concerted action, so we had to think of an acronym that began with CA. So I, I came up with Concerted Action Polyp Prevention. But then in 1993, just as we started that trial, we were involved in finding the first of the genes for Lynch syndrome. We had a big family in Northumberland where there were lots of people like Drew's family, and there were three generations of cancer in the family. [00:14:31] So CaPP2 was immediately born in my head. In 1999, we had our first recruit, and we recruited until 2005. We found, in total, 1,000 people in 16 countries to join in, and we gave them two aspirins a day or two dummy tablets. Two aspirins is quite a big dose, but back in my day when I was a junior doctor, we used to give many more tablets of aspirin to people with arthritis. [00:14:57] So two tablets wasn't such a big deal. Nowadays, it's seen as a very high dose. And it worked. Basically, to cut to the chase, when we looked in 2010, the people who were getting the aspirin were getting less bowel cancers. In fact, it was a 50% reduction. So the people who took two aspirins had half as many bowel cancers and fewer cancers of other types as well. [00:15:19] We realised, although, at this point, immediately we saw that it was working, we knew we'd need to do another trial to see whether a smaller dose of aspirin would be just as effective. So CaPP3 began, and the great news is that what we'll be reporting in the journals in the next few days when it gets published, is that the people who were taking  CaPP3 aspirin in any dose were tracking exactly the same as the 600-milligram group in CaPP2. [00:15:46] So we're pretty sure that it works. We're pretty sure that the small dose is just as good. And the great news was that we had fewer side effects in that group. And so in fact, no one had to go to hospital for a transfusion or anything, you know, like that. Whereas in the 600-milligram group, we had a few people who needed treatment because, as you know, and everyone knows, if you take aspirin, there's a higher chance of having an ulcer that causes a bleed. [00:16:10] And that was always the anxiety. But people like Drew were courageous enough to take the chance because they knew we needed to know the answer to this. And of course, when you compare it to the risk of getting cancer, taking an aspirin is a relatively small risk. [00:16:26] Sharon: So, what were your kind of considerations when you were designing the trial, having that knowledge? [00:16:32] John: Well, the first thing is it has to be fully informed consent, which means that you have to explain to people what that risk is. The important thing about aspirin is that doctors have a much worse opinion of it than it deserves because if you work in a hospital, you'll often see people coming in who've had a bleed. [00:16:48] It's not always caused by the aspirin. The thing is, if you're coming with a bleed and you're on aspirin, everyone blames the aspirin. Right. About half of them would've happened anyway. In fact, the, the irritation of the stomach is much more of a problem in older people So in fact, the average age of the people in CaPP2 and CaPP3 was about 45, 46 when they started. [00:17:08] Drew was a little bit older, but, but people in that sort of middle age group are much, much less likely to get into trouble than people in their 70s and 80s. And it's people also who've had a history of ulcers that have a bigger problem. We also knew that if you had a stomach infection called H. Pylori, which is itself a risk factor for cancer, and about one in six people carry that bug, and we knew that if we fixed that with antibiotics, that would significantly reduce the risk of bleeding as well. [00:17:37] So it was a manageable risk. It was something we could share with people. They knew they were taking a bit of a chance. But actually a good way of putting it in terms of the risk, for people in middle age, the risk of a low dose of aspirin is about the same as the risk of having a colonoscopy, which is very small, but it isn't completely without risk. [00:17:56] Sharon: Yeah, and Drew, kind of like hearing this sort of incredible, like, backstory about how we've got to these trials and where we are today What was your experience like as a kind of participant of this trial? [00:18:08] Drew: I understood I was going to be on 100, 300, or 600, but wouldn't know for at least three years, or was it five years? I can't remember. [00:18:15] And then sometime later in the post we got these packs, and it was ... I remember at the time thinking it was like a rather dull advent calendar - ... in that you'd have the days of the week- ... with the little, with the little windows, and you'd, you'd pop the tablets out three times a day and take them. [00:18:31] So I did that. I think, you know, I, I don't think I ever missed a day or whatever. Initially, I thought I must be on a really low dose, because I didn't actually notice any side effects. You know, I remember saying to my wife, I said, "Oh, I think I must be on the lowest dose, because I don't see any side effects." [00:18:46] It was a surprise years later when I was told actually I'd been taking 600, so. [00:18:51] Sharon: Wow. [00:18:52] Drew: It was quite an easy experience really. [00:18:54] John: We had a lot of problems. We had to pack the aspirin in six-month packs, because it was very expensive to pack this stuff up. It cost... We got the aspirin free from the Bayer company, but it cost us more than a million pounds to actually put it in, in the packs to satisfy the regulations. [00:19:10] Uh, and a lot of people complained that the packs were a bit big and awkward, but that was just, you know, a constraint. But it was not that big a deal once people got into it. But we did get a lot of complaints about the size of the packets, which we couldn't do anything about that. [00:19:24] Drew: They came regularly through the post, and, you know, so every three months or whatever I got another supply, and I just carried on taking them. [00:19:30] Yeah, so. [00:19:31] Sharon: What was going through your mind when you were kind of waiting for this potential outcome, Drew? Because you, like you say, it was, you know, it was a long time taking part. What was... Especially as you were opening your, you know, your package a day, knowing exactly what you were going to get. [00:19:44] Drew: Well, I, I kind of knew it would be a long-term thing. [00:19:47] I think I was committed for five years initially. But I carried on taking the aspirin for another probably five years after that. So yeah, I was just sort of happy to take the aspirin and then sort of wait to see what the results would be. As I say, that I didn't really notice any side effects, so I wasn't really worried that it was having any detrimental effect on me. [00:20:09] So I was curious to see what the, what the results would be. [00:20:12] Sharon: Yeah. John, the trial has provided like the evidence that, you know, low-dose aspirin can prevent bowel cancer. But are there any challenges that still exist with translating this research into clinic and ultimately patient care? [00:20:26] John: Well, yes, and I'm going to hand back to Katie, who's actually leading the charge on, on getting it into practice as well. [00:20:32] But just to say that I, I'm actually now literally on my other computer finalising my bid to go back to Cancer Research UK because we want to go for three more years. Wow. We said that we would follow people for 10 years after they'd finished their ... or after they'd started, so, you know, for at least 10 years. [00:20:50] So the last person to join didn't finish until 2024, so we won't get to that person. It's Robin and one of my patients. We won't get to Robin's 10-year anniversary until 2029. Oh, yeah. By which time, obviously, Drew will be even further on. But that will give us at least 10 years of follow-up because we know that there is this delayed effect, and that was seen right back at the beginning when people looked, for example, the nurses study in America, where they followed 86,000 nurses and just asked them if they took aspirin. [00:21:18] And nothing happened for 10 years, but those who were taking aspirin for more than 10 years saw a benefit. So in the general population, it probably takes that long to kick in. And so we need to keep going for just a while longer. It's not as expensive now because we're not giving people aspirin anymore. [00:21:33] Sharon: Yeah. [00:21:34] John: But one of the reasons we g- we made Drew's dose blind was because we wanted to know what the side effects would be when you didn't know how much you were getting There's a danger if you're getting a higher dose, you're more likely to complain. And actually, it did work out that the people on the lowest dose had the fewest side effects, even slight side effects. [00:21:51] The only thing we can't escape from is if you're taking aspirin, you get bruising more easily because it blocks the platelets, which are the little tiny blood cells which plug up little holes in your blood vessels when they leak. The good news is we now know that platelets turn out to be right, a major factor in triggering cancer. [00:22:09] And so the aspirin, by blocking the platelets, is actually reducing the risk of cancer, but also reducing the risk of cancer spreading in the body. So this is new research, and we've got another big research project in collaboration with a team in Cambridge who are, uh, pursuing this. Also, the other exciting news is that my other partner, Ruth Langley, is running a big trial of people with cancer, and those who are given aspirin as part of their treatment have less likelihood of getting spreading cancer later on. [00:22:39] So the aspirin is clearly doing something good at many levels in the system. Surprisingly, and we think it might be partly, partly because we used to have a lot of salicylate in our diet, which is what aspirin's made from. And we think that maybe we're putting back something that the body actually was used to having. [00:22:57] Yeah. But modern diets don't contain any, any salicylate because of the way we prepare our food. So it may well be that a little bit of aspirin's a good thing for everybody, but obviously, that's a choice that each person will have to make. [00:23:09] Sharon: Yeah. I mean, it's a real powerhouse of a, of a drug essentially, which you're finding out more about its benefits as, uh, as research goes on. [00:23:18] So Katie, can you just give us a bit of a broad overview of Genomics England's new adults program, which is kind of looking at this sort of area of work and, and what, how can it benefit people? [00:23:29] Katie: Yeah. Thank you, Sharon. So, the adults programme at Genomics England is being funded by government, and the government wrote about it in the 10-year NHS Health Plan, the Life Science Sector Plan to run a large-scale genomics population study. [00:23:44] So looking at how we can obtain genetic information from people in the population and look at more proactive and preventative healthcare, and can we generate evidence on where, how, and why the NHS should start applying genomics into kind of more population health measures. So, there's sort of two sides to this. [00:24:05] So the first is thinking about pharmacogenomics, which is basically about how genetic factors influence how we respond to drugs. So lots of people have had experiences of having side effects from drugs, we've just been talking about that with aspirin, or for drugs not working so well for them. And we know that there are certain drugs that genetic factors can influence whether you should take the drug at all, or if you do, what dose you should take, whether it's going to work for you or not, whether you might be more likely to get side effects or adverse reactions. [00:24:34] So part of the programme's looking at that. And then the other half of the programme will be looking at sort of is, are the genetic factors relevant for sort of serious and high-risk conditions in the adult population? So we could take bowel cancer as an example of that, a common condition, breast cancer, you know, common cancers or cardiovascular disease. [00:24:58] We know there are certain genetic factors for some people that have significantly increased their chance of developing those serious adult onset conditions. Can we find those people in the population and then put measures in place to prevent that? So, you know, even just thinking about Drew's story, he didn't have a family history of cancer. [00:25:16] The first time that he knew he had Lynch syndrome, he'd already developed bowel cancer. And we know that many people that have Lynch syndrome or other high-risk cancer genes are unaware of their status in the population, and so, um, the idea of this program is to really look at, well, if we were to, to look for some of these very high-risk genes in the general population, could we then put measures in place to reduce the chance of them developing the serious condition as a consequence? [00:25:44] So instead of Drew presenting with his bowel cancer, we'd actually already picked it up, despite the fact he doesn't have a family history, and we'd offered him, let's say, aspirin if we'd known the information at the time, and we could maybe have prevented him from developing bowel cancer. [00:25:58] So it's really exploring looking at that a little bit more. [00:26:02] Where can we get genetic information in the population? Where might there be a really well-evidenced, like all the work John's done over 40 years, is really well-evidenced now. Yeah. Yeah. Where are there these opportunities for us to turn the dial on some of these common adult onset conditions? [00:26:20] Sharon: What other challenges do you think with getting this out there do you see? [00:26:25] Katie: Uh, I think there's, there's lots of challenges. I think it's a really com- ... complex programme of work. The first thing is that the risks might be different for people in a population than have a family history. So where I've worked for, for years, and John as well in, in clinical genetics, we've seen the highest risk people, the people with lots and lots of cancer in their family because they're the people that are presented to healthcare services. So we've worked out the risks based on that population. It will be really different when we move to the population setting. We'll find fewer people, and the risks might be lower because there might be other factors that are giving them a lower risk. But that's not to say the risk is zero. [00:27:05] It's probably still raised. So then what we need to do is we need to consider, okay, well, what can we do to intervene, taking into account this change of context from people that we found through clinical services to people that we see in the population. And aspirin is a great example of this. [00:27:22] So, you know, if we find that someone has a Lynch syndrome gene, then taking aspirin, unless there's a really good reason for them not to take aspirin, is almost certainly going to be low cost to the NHS and really significantly reduce the chance of them developing bowel cancer with a low risk profile. So where are those opportunities? [00:27:41] And that isn't clear cut, and that's why we need a large scale research programme that can try to help the NHS answer some of those questions, so it can decide how best to spend its money in, in the people that are most likely to benefit from it with the least amount of risk or harm to them. [00:27:58] Sharon: That makes sense. And, and so, you know, going to you, Drew, what are your kind of thoughts on some of the challenges that Katie's highlighted? And is there anything else that you think needs to be improved in better supporting people living with inherited risk of cancer in the future? [00:28:14] Drew: In the brief sort of 10, 15 years or whatever since I've been s- suffering, awareness has increased greatly. [00:28:21] I mean, for example, my GP now knows about Lynch syndrome, whereas I don't think she did when I was first diagnosed, and I think there is a little bit more awareness out there, but I still think it's a lot less than there would be for, say, for breast cancer. So for example, when a high-profile personality reveals they've got breast cancer, you often get information about inherited risks. [00:28:44] You don't seem to get that with colon cancer. You know, when it's announced that so-and-so has died or is whatever, you don't get that same, you know, it, it might be a genetic thing. I mean, when I was first told people that I had bowel cancer, the response I got usually was, "Oh, poor diet, was it?" [00:29:04] And I always felt a bit upset, that, you know, actually my diet was fairly healthy. And that was the assumption that people had. So I think anything that gets the message out there that there is a risk, an inherited risk, I'm not sure what the statistics are now, Katie, is it one in 400 people might be a Lynch syndrome carrier or something like that? [00:29:24] You know, it's relatively high for something that is, if you know in advance you're at risk, you can do something about it. But like me, you know, I waited until it was too late, because I didn't know, and then had to have the surgery, so anything that promotes the message that there is a risk. I know some people don't want to know about their genetic makeup. Obviously, that's a choice. But I think to give people, as many people as possible, the choice must be a good thing. [00:29:54] Sharon: Yeah, absolutely. And I think one thing I've noticed through this thread is the sort of theme of funding and what gets funding and the amount of time it takes to, to kind of get that funding. [00:30:05] Is there anything you wanted to add around the kind of funding model, around why some things get funded, you know, uh, more prominent, like Drew's point, obviously, talks about if someone high profile kind of comes forward and says XYZ, that gets the spotlight shone on it, and there might be research going that direction compared to s- to, to other cancers. [00:30:23] John: So maybe I could speak at that. So partly because of my experience, I've now been made chairman of the grant committee at Cancer Research UK for prevention and population research. And there is a real drive to push more resource into prevention for the obvious reasons. [00:30:39] Katie: Yeah. [00:30:39] John: And also, it's got to be remembered, it's very difficult for the drug companies to fund this because it takes such a long time that the drug's- Mm [00:30:46] out of its patent before they actually get to use it. So, it's very difficult from a business point of view to fund research into prevention. But they are keen to help us, uh, but we really need sort of central government and the charities to focus on prevention if it's going to make a difference. [00:31:02] And just on Drew's point on diet, I mean, diet is still important even if you have Lynch syndrome. In our CaPP2 trial, the people who were overweight were more than double the risk of cancer. So it's not like an either/or. If you've got a higher genetic risk and you have a bad diet, then that's, you know, is going to contribute. [00:31:21] But the other exciting thing is, of course, we now have medical ways of treating obesity in, in people. So, one of the interesting areas is whether we should be, in the same way as we are for other high-risk populations with overweight, we should be giving overweight people with Lynch syndrome, help to lose weight because that will also reduce their risk. [00:31:41] It's also worth just dropping in at the last moment here is that this is also a good news story in terms of treatment and further prevention. We now have a new class of drugs called immune checkpoint inhibitors, which specifically target the types of cancer that Drew had and are much more effective in curing them And also, we've just been given funding to do a project called LynchVax, which I'll be helping with, but it's led by David Church in Oxford. [00:32:05] And this is developing a vaccine against cancers in people with Lynch syndrome. The great news is it'll probably work alongside aspirin because we know the aspirin is enhancing the immune response. So the two together may make this a curable condition. [00:32:18] Sharon: That's actually incredible. I mean, that, it gives so much hope for people. [00:32:23] And I just wanted to find out if you had any more kind of reflections as we close, because we're going to come to the end of our podcast today. If there's anything more that you wanted to share, anything that has been missed, or anything that you want our listeners to know, and I think I'm gonna come to you, Drew, first, because you're the person who's had to sort of live through this and, and go through this journey along the way. [00:32:41] Drew: I think just basically, if you're not sure, get tested. Obviously, there are financial constraints. I'm sure that running a DNA test is quite an expensive business. But I think if you've got any history of bowel cancer in the family, you've got any concerns about your health, speak to a GP and see if you can get tested as quickly as possible. [00:33:00] And then, to get a better message out there that there are risks of inherited colon and other similar cancers, so. [00:33:11] Sharon: Yeah, so it's getting that, messaging out, um, for people to understand more and make those informed choices. And Katie? [00:33:18] Katie: I mean, I would say that the power of, of our, you know, NHS and our academia and, and our healthcare system has been collaboration. [00:33:26] Sharon: Yeah. [00:33:27] Katie: There's so many moving parts. There's commissioners, there's funding, there's the evidence, there's research, there's healthcare implementation. The UK's a really amazing place to work in genomic medicine, and I think that's partly because of the amazing collaborations that we have, and the way that we can translate research into healthcare as John's team have done with this amazing study. [00:33:48] So let's all keep working together, please. [00:33:52] Sharon: Absolutely. And John, it feels like this is your lifetime's work. [00:33:58] John: Well, I've become aspirin man, it wasn't intended. But Katie's done fantastic work in her role as chair of the Cancer Genetics Group in the UK, so we've now implemented a, [00:34:06] we're the first in the world to really make this an absolute directive to the GPs and all, to all doctors to say, "People with Lynch syndrome need to be offered aspirin." And so that's a great step forward. But we also need to get it into the British National Formulary, and I'm working with their team so that the GPs are empowered to do this. [00:34:24] It's actually part of their care package. But I would just say we've still got a long way to go. We've now got a national list of all the people with Lynch syndrome, like Drew, to make sure we offer them all a colonoscopy, but there are only 14,000 people after several years of really pushing. [00:34:40] Sharon: Right. [00:34:40] John: We think in the national population in all ages, it's about 1 in 300. That's a lot of people. That means there's about 150,000 people like Drew in the country, and we've only found 10% of them. So we can't just rely on family history for all the reasons Drew explained. You know, I mean, Drew's dad probably died of Lynch syndrome, but we don't know because we've lost that record. [00:35:02] So now we're checking every bowel cancer to see if it might be caused by Lynch, and that programme is now kicking in, and we're picking up a lot more gene carriers as a result of that. But there's still a long way to go to get co- get people aware of Lynch syndrome, to think of it when someone presents with a cancer, not just of the bowel, but in the womb, in the kidney, in other parts of the body. [00:35:23] It's not just the bowel, but that's the most important group. [00:35:26] Sharon: Yeah. [00:35:26] John: So there's still a long way to go. [00:35:28] Sharon: Where you've come to now is still an incredible achievement, even though we've still got a long way to go, and I don't think we should ever lose sight of that. So we're going to wrap it up there. Thank you to our guests, Katie Snape, Professor Sir John Burn, and Drew Hyde, for joining me today as we discuss cancer prevention. [00:35:48] If you'd like to hear more like this, please subscribe to Behind the Genes on your favourite podcast app, and thank you for listening. I've been your host, Sharon Jones, and Behind the Genes is produced by Deanna Barac, Florence Cornish, Sophie McLachlan, and Dave Howard at Bespoken Media.  

This episode features Prof. Christopher Stewart PhD from Newcastle University (UK), speaking about the factors affecting gut microbiota development in both non-preterm and preterm infants. Prof. Stewart started in the field of environmental microbial ecology and then came to work in human microbiome research. He was involved in the landmark TEDDY study, which aimed to find gut microbial markers of type 1 diabetes (T1D). Although no microbial triggers of T1D were identified, the study found a number of factors that impact gut microbiome development: for example, sex, geographical location, and living with furry animals. Still, most of the variation seen in the infant gut microbiota remains unaccounted for. He noted that infants are exposed to both vaginal and gastrointestinal microorganisms during vaginal birth. In C-section-born infants, seeding of the maternal vaginal and gut microbiota may be promising, but current methods are imprecise and safety has not been established. Furthermore, diet takes over as a primary driver of gut microbiota a few weeks after birth. Prof. Stewart talked about human milk oligosaccharides (HMOs), well known to be utilized by bifidobacteria in the infant gut. His lab recently published the surprising finding that Clostridium species can also utilize HMOs – and while at first this was thought to be detrimental for the infant, further investigation showed that the HMO-utilizing Clostridium may lack the genes for producing specific toxins and end up being protective for the infant gut. Together, the microbial community in the gut may use the full suite of HMO substrates reaching the infant gut. Preterm infants are a population that needs more attention. Antibiotics affect their gut microbiomes – often in a negative way, but for the overall benefit of the baby. His lab is currently funded to study how probiotics affect the preterm infant gut microbiota, and to find strategies for more personalized approaches to administering probiotics in this population. Episode abbreviations and links: TEDDY study, revealing factors affecting gut microbiota development between 3 and 46 months of age: Temporal development of the gut microbiome in early childhood from the TEDDY study Study on how Clostridium species utilize HMOs: Clostridia from preterm infants metabolize human milk oligosaccharides to suppress pathobionts and modulate intestinal function in organoids Study on how NEC risk is linked with HMOs: Human milk oligosaccharide DSLNT and gut microbiome in preterm infants predicts necrotising enterocolitis Publication on how probiotics impact the gut microbiota in preterm infants: Strain-specific impacts of probiotics are a significant driver of gut microbiome development in very preterm infants Some similar results have come from the CHILD Cohort Study, described here Find Prof. Stewart on LinkedIn, and learn more about his research on this website About Prof. Christopher Stewart: Professor Christopher Stewart is an internationally recognised leader in human microbiome research. He earned his PhD in Microbial Ecology from Northumbria University (UK), followed by postdoctoral training at Baylor College of Medicine (Houston, Texas), before establishing his research group at Newcastle University in 2018. His pioneering work focuses on microbial-host interactions in the gut, particularly in infants born extremely premature (

Have you ever stayed in the bath or swimming pool for ages and noticed that your fingers and toes went all wrinkly? Well, 11-year-old Maya from London wanted to know why that happens.She joins host Eloise to get the answer from biologist Tom Smulders from Newcastle University on the first episode of our second season! There's an experiment in this episode which you can try out too while you listen. If you want to join in, prepare a bowl of warm water.A podcast from The Conversation, the independent not-for-profit news organisation that brings you news and analysis straight from academic experts. Full credits available here.This season is supported by the University of Southampton in the UK, a world-leading research-intensive university with a global network of international students and campuses in Malaysia and Delhi. Are you a curious kid with a question? Pop it in an email, or record it and send us the audio to curiouskids@theconversation.com.

In this episode, I speak with Rob Wood, Portfolio Investor and Founder of the Rob Wood Enterprising Futures Academy, about entrepreneurship, scale, reinvention and widening access to enterprise. Rob founded STEM Healthcare in 2007, scaling it internationally before its acquisition by UDG Healthcare. Today, he is an active portfolio investor, working with technology-enabled pharma services and AI-driven healthcare businesses, including AdvanceAI. Through the Rob Wood Enterprising Futures Academy, created in partnership with Newcastle University in the UK, he is also helping young people build the confidence, tools and support to succeed in life and business. Connect with Shirley at ShirleyKavanagh.com and on LinkedIn. To learn more about Rob's work, visit the Rob Wood Enterprising Futures Academy or connect with him on LinkedIn

In this episode of Joint Ventures, hosts Jack Arnold, MBBS, PhD, an academic clinical lecturer in rheumatology at the University of Leeds, and Rihards Buss, MD, a consultant rheumatologist at Freeman Hospital, Newcastle, are joined by guest Lucy Carter, MBBS, PhD, a consultant rheumatologist at Newcastle upon Tyne NHS Foundation Trust and honorary clinical senior lecturer at Newcastle University, to examine nearly 2 decades of B cell–targeted therapy in rheumatic disease — a story that has proven considerably more complicated than its early promise suggested.Carter, Arnold, and Buss trace the mixed legacy of rituximab in lupus and Sjögren disease and examining how incomplete B cell depletion, BAFF-driven rebound, and trial design limitations may have contributed to disappointing early results. The discussion then turns to newer approaches such as obinutuzumab, whose positive REGENCY and ALLEGORY trial data in lupus nephritis and systemic lupus erythematosus suggest that deeper, more durable B cell depletion may improve outcomes, while emerging CAR-T data raise broader questions about the future role of intensive immune reprogramming in autoimmune disease.

What was life like for young people in twentieth century Britain? In We Have Come to Be Destroyed: Growing Up in Cold War Britain (Yale University Press, 2026), Dr Laura Tisdall, a Senior Lecturer in Modern British History at Newcastle University tells the story of this era through the eyes of children and young people, offering a radical reinterpretation of Britain's Cold War age. The book offers a wide range of perspectives, from young people's hopes and anxieties for the future, through popular culture during the Cold War, to changes in schools and the education system. The analysis also draws on detailed engagements with feminist and gay rights campaigns, and highlights the experiences of young people of colour, blending microhistories of individual experience with a broader narrative that transforms our existing knowledge of the Cold War. The book will be essential reading across the arts and humanities, as well as for social science scholars and anyone interested in knowing more about recent British history. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/new-books-network

What was life like for young people in twentieth century Britain? In We Have Come to Be Destroyed: Growing Up in Cold War Britain (Yale University Press, 2026), Dr Laura Tisdall, a Senior Lecturer in Modern British History at Newcastle University tells the story of this era through the eyes of children and young people, offering a radical reinterpretation of Britain's Cold War age. The book offers a wide range of perspectives, from young people's hopes and anxieties for the future, through popular culture during the Cold War, to changes in schools and the education system. The analysis also draws on detailed engagements with feminist and gay rights campaigns, and highlights the experiences of young people of colour, blending microhistories of individual experience with a broader narrative that transforms our existing knowledge of the Cold War. The book will be essential reading across the arts and humanities, as well as for social science scholars and anyone interested in knowing more about recent British history. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/gender-studies

What was life like for young people in twentieth century Britain? In We Have Come to Be Destroyed: Growing Up in Cold War Britain (Yale University Press, 2026), Dr Laura Tisdall, a Senior Lecturer in Modern British History at Newcastle University tells the story of this era through the eyes of children and young people, offering a radical reinterpretation of Britain's Cold War age. The book offers a wide range of perspectives, from young people's hopes and anxieties for the future, through popular culture during the Cold War, to changes in schools and the education system. The analysis also draws on detailed engagements with feminist and gay rights campaigns, and highlights the experiences of young people of colour, blending microhistories of individual experience with a broader narrative that transforms our existing knowledge of the Cold War. The book will be essential reading across the arts and humanities, as well as for social science scholars and anyone interested in knowing more about recent British history. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/critical-theory

What was life like for young people in twentieth century Britain? In We Have Come to Be Destroyed: Growing Up in Cold War Britain (Yale University Press, 2026), Dr Laura Tisdall, a Senior Lecturer in Modern British History at Newcastle University tells the story of this era through the eyes of children and young people, offering a radical reinterpretation of Britain's Cold War age. The book offers a wide range of perspectives, from young people's hopes and anxieties for the future, through popular culture during the Cold War, to changes in schools and the education system. The analysis also draws on detailed engagements with feminist and gay rights campaigns, and highlights the experiences of young people of colour, blending microhistories of individual experience with a broader narrative that transforms our existing knowledge of the Cold War. The book will be essential reading across the arts and humanities, as well as for social science scholars and anyone interested in knowing more about recent British history. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/lgbtq-studies

What was life like for young people in twentieth century Britain? In We Have Come to Be Destroyed: Growing Up in Cold War Britain (Yale University Press, 2026), Dr Laura Tisdall, a Senior Lecturer in Modern British History at Newcastle University tells the story of this era through the eyes of children and young people, offering a radical reinterpretation of Britain's Cold War age. The book offers a wide range of perspectives, from young people's hopes and anxieties for the future, through popular culture during the Cold War, to changes in schools and the education system. The analysis also draws on detailed engagements with feminist and gay rights campaigns, and highlights the experiences of young people of colour, blending microhistories of individual experience with a broader narrative that transforms our existing knowledge of the Cold War. The book will be essential reading across the arts and humanities, as well as for social science scholars and anyone interested in knowing more about recent British history. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/british-studies

This week on The Beat, CTSNet Editor-in-Chief Joel Dunning spoke with Dr. Enoch Akowuah, an academic consultant cardiothoracic surgeon at Newcastle University and South Tees NHS Foundation Trust, UK, and Dr. Matthias Raschpichler, a cardiac surgeon at Leipzig Heart Center, Germany, about the REPEAT trial. Chapters 00:00 Intro 02:21 JANS 1, NOBLE Trial 07:14 JANS 2, Ischemic Mitral Regurg MVR 08:58 JANS 3, Pregnancy Outcomes AVR 11:19 JANS 4, MCS LVAD Candidates 13:06 Video 1, Thoracoplasty 14:58 Video 2, Nuss Procedure After Ravitch 16:42 Video 3, Traumatic Right Main Bronchus 19:04 REPEAT Trial, Bioprostheses 32:22 Upcoming Events 32:46 Closing They discussed the trial's objectives, including what it is, why it is needed, and its overall goals. The setup of the trial was also examined, covering aspects such as funding, composite outcome, and follow-up procedures. Additionally, they addressed the target number of patients required for recruitment and the efforts involved in recruiting patients and centers to participate in the trial. They emphasized the overall significance of the trial, outlining what is necessary for its success and highlighting the importance of collaboration among heart teams. Joel also highlights recent JANS articles on percutaneous coronary intervention vs coronary artery bypass grafting for unprotected left main stenosis, a two-decade experience on the outcomes of mitral valve repair in ischemic mitral regurgitation, maternal, valvular and fetal outcomes of pregnancy following aortic valve replacement, and temporary mechanical circulatory support in left ventricular assist device candidates with right ventricular dysfunction. In addition, Joel explores if forgotten techniques of thoracoplasty with latissimus dorsi myoplasty are relevant today, the Nuss procedure after previous Ravitch operation, and uniportal VATS repair of traumatic right main bronchus transection following blunt chest injury. Before closing, Joel highlights upcoming events in CT surgery.   JANS Items Mentioned Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting for Unprotected Left Main Stenosis: 10-Year Final Results From the Randomised, Open-Label, Non-Inferiority NOBLE Trial Outcomes of Mitral Valve Repair in Ischemic Mitral Regurgitation: A Two-Decade Experience Maternal, Valvular and Foetal Outcomes of Pregnancy Following Aortic Valve Replacement  Temporary Mechanical Circulatory Support in Left Ventricular Assist Device Candidates With Right Ventricular Dysfunction: Acuity Without Long-Term Futility CTSNet Content Mentioned Are the Forgotten Techniques of Thoracoplasty With Latissimus Dorsi Myoplasty Relevant Today?  Nuss Procedure After Previous Ravitch Operation  Uniportal VATS Repair of Traumatic Right Main Bronchus Transection Following Blunt Chest Injury  Other Items Mentioned The REPEAT Trial Career Center CTSNet Events Disclaimer The information and views presented on CTSNet.org represent the views of the authors and contributors of the material and not of CTSNet. Please review our full disclaimer page here.

April 25 marked the 130 anniversary of women voting for the first time in an Australian election. It is a history marred with struggle, protest, and women standing up for their rights in a patriarchal society. David Barr talks to Dr Alice Neikirk, Criminology lecturer at Newcastle University, about the groundbreaking South Australian election of [...]Read More... from 130 Years of Women Voting in Australia – An Interview

In this episode, Ray Cochrane breaks down a reversible conductive glue from Newcastle University that could replace solder and finally make electronics recycling work. Additional stories cover China widening its clean energy lead, DeepMind’s AlphaEvolve scoring wins from genomics to Google’s database, Anthropic’s $200 million partnership with the Gates Foundation, Intel teaming up with McLaren Racing, and end-to-end encrypted RCS rolling out in beta. – Want to start a podcast? Its easy to get started! Sign-up at Blubrry – Thinking of buying a Starlink? Use my link to support the show. Subscribe to the Newsletter. Email Ray if you want to get in touch! Like and Follow Geek News Central’s Facebook Page. Support my Show Sponsor: Best Godaddy Promo Codes Get 1Password Full Summary Cochrane opens the show with a deep dive into Newcastle University’s reversible conductive glue, a water-based adhesive that could finally make electronics recycling economically viable. He frames the e-waste problem first: 62 billion kilos a year, with less than a quarter ever recycled. Then he walks through the silver nanoparticle chemistry, the lead-free angle on traditional solder, and the geopolitical stakes of critical mineral recovery. From there the episode pivots through energy, AI, hardware, open source, data research, space, science, and consumer privacy. A Reversible Conductive Glue That Could Replace Solder A team at Newcastle University has developed a water-based glue that conducts electricity well enough to replace solder. Unlike solder, however, the glue releases cleanly with a quick rinse of acetone or an alkaline bath. The breakthrough relies on silver nanoparticles suspended in a water-based binder. Consequently, components can be recovered intact, opening a viable path to electronics recycling at scale. Co-investigator Volker Pickert framed the second prize directly: solder has the best conductivity, but the best formulations contain lead. China Widens Its Clean Energy Lead A new Atlas Public Policy report shows Chinese firms accounted for 55 percent of $1.1 trillion in global clean energy manufacturing investment between 2019 and 2025. Battery manufacturing alone pulled in nearly half of that money. Meanwhile, U.S. companies have actively retreated from those same industries. With the Strait of Hormuz currently closed, supply chain ownership in solar, wind, and batteries matters more than ever. A separate Ember analysis showed Chinese solar panel exports doubled in March alone. DeepMind’s AlphaEvolve Scores Real Wins DeepMind published an update on AlphaEvolve, its Gemini-powered AI coding agent. The system cut genomic variant detection errors by 30 percent. Additionally, it lifted AC Optimal Power Flow feasibility from 14 to over 88 percent on the electrical grid. AlphaEvolve also found a better cache replacement policy in two days that would have taken human engineers months. Furthermore, it reduced write amplification in Google’s Spanner database by 20 percent. The pattern shows applied AI sticking, not as a chatbot but as a quiet optimizer. Anthropic and Gates Foundation Commit $200 Million Anthropic announced a four-year, $200 million partnership with the Gates Foundation across three pillars. The biggest pillar targets global health and life sciences in low and middle-income countries. Notably, the research scope includes polio, HPV, and preeclampsia. A second pillar covers AI in education across the U.S., sub-Saharan Africa, and India, in partnership with the Global AI for Learning Alliance. Finally, an economic mobility pillar focuses on agricultural productivity and crop benchmarks. Google’s AI Educator Series Launches Free Google rolled out the first 20-plus sessions of its AI Educator Series this week. The free AI literacy training targets the roughly 6 million K-12 and higher education teachers across the U.S. Modules are designed as short, snackable trainings teachers can finish in a prep period or a lunch break. Additionally, stackable workshops let educators build credentials over time. Importantly, the program requires no institutional subscription. Amazon Bedrock Prompt Optimization Goes GA Amazon Bedrock dropped its Advanced Prompt Optimization tool, now generally available across most major regions. The feature rewrites prompts to perform better on specific models and automates prompt migration when switching between models. Furthermore, a built-in evaluation feedback loop lets users benchmark against up to five models side by side. The default judge model is Claude Sonnet 4.6. Consequently, teams can stop hand-tuning string templates and focus on product work. Sponsor: GoDaddy Economy hosting $6.99/month, WordPress hosting $12.99/month, domains $11.99. Website builder trial available. Use codes at geeknewscentral.com/godaddy to support the show. Arm AGI CPU and Red Hat Go Production-Ready on Agentic AI Arm and Red Hat expanded their collaboration around Arm’s AGI CPU, which is Arm’s branding for its agentic AI chip family. The deal brings Red Hat Enterprise Linux and OpenShift to the chip as a production-ready stack. Hardware specifications include 136 Neoverse V3 cores, 96 PCIe Gen6 lanes, and 12 channels of DDR5-8800 memory in a 300-watt thermal envelope. Availability lands in Q4 through Supermicro, Lenovo, and ASRock Rack. Intel Becomes McLaren Racing’s Official Compute Partner Intel announced a multi-year deal as the official compute partner for McLaren Racing. The agreement covers the McLaren Mastercard Formula 1 team, Arrow McLaren IndyCar, and McLaren F1 Sim Racing. Trackside edge compute will power real-time race decisions, while Xeon and Core Ultra silicon drive Computational Fluid Dynamics and digital twin work. Consequently, design iterations that once took weeks now collapse to days. The deal puts Intel silicon in front of every CTO watching a Grand Prix. Rust Lands 13 Google Summer of Code Projects The Rust Project landed 13 accepted projects in Google Summer of Code 2026. Out of 96 proposals, a 50 percent jump from last year, the project selected 13. Notably, three returning contributors from prior years are back. Mentors flagged a noticeable share of AI-generated submissions as a growing challenge. Furthermore, the real bottleneck remains mentor capacity rather than funding. GitHub Innovation Graph Maps Digital Complexity Researchers used GitHub Innovation Graph data to predict GDP, inequality, and emissions through the Economic Complexity Index, or ECI. Countries are compared to kitchens; the more variety and sophistication in software output, the higher the score. Germany ranks first, followed by Australia and Canada. The U.S. lands at sixth. However, the dataset only captures public GitHub activity, leaving most proprietary software invisible. NASA and Eta Space Prepare Cryogenic Fuel Demo NASA is teaming with Eta Space on an in-orbit demonstration called LOXSAT, short for Liquid Oxygen Flight Demonstration. The nine-month mission tests cryogenic fluid management techniques required for in-space propellant depots. Launch is no earlier than July 17 aboard a Rocket Lab Electron from the Mahia Peninsula in New Zealand. Successful refueling in orbit could reshape what is possible for deep-space missions to the Moon and Mars. Stealth Magma Surge Under São Jorge Surprises Researchers Researchers in the UK and Spain published in Nature Communications on a 2022 magma surge under São Jorge Island in the Azores. The surge climbed from more than 20 kilometers underground to 1.6 kilometers below the surface. Surprisingly, most of the thousands of earthquakes happened after the magma stalled, not during the climb. Consequently, scientists are calling it a stealth surge and a failed eruption. A primed magma chamber now sits closer to the surface than before. End-to-End Encrypted RCS Begins Rolling Out Apple and Google led a cross-industry effort to roll out end-to-end encryption for RCS messaging. As of May 11, the feature is rolling out in beta on both platforms. Importantly, encryption is on by default and auto-applies to new and existing conversations. A lock icon in the chat indicates active end-to-end encryption. This quietly raises baseline privacy for billions of cross-platform messages. Cochrane signs off with the usual ecosystem mentions: GNC Insider at geeknewscentral.com/insider, the show newsletter, and modern podcast app recommendations at podcastapps.com. The post A Reversible Glue that could Replace Solder #1865 appeared first on Geek News Central.

At just 27, Ali Hashemizadeh is doing things most dentists twice his age haven't managed — two private associate roles, a growing reputation as an endodontist, and the kind of self-awareness that usually takes a decade to develop. In this episode, Payman sits down with the Newcastle-based, Aberdeen-raised, Iranian dentist to trace the path from a rocky first year on the NHS to finding his feet in private practice. Ali talks candidly about the complaint that rocked him early in his career, the perspective shift it forced, and why he's genuinely glad it happened. It's a conversation about curiosity, resilience, and the quiet power of just cracking on.In This Episode00:00:50 – Introduction: Ali Hashemizadeh00:03:45 – Lifelong learning00:07:25 – The future of dental events00:14:30 – Optimism as a work philosophy00:15:35 – NHS complaint, first job00:19:40 – Resilience and perspective00:21:10 – Going private early00:22:25 – Becoming the endo guy00:25:55 – Generalist or specialist?00:26:50 – The disease of the twenties00:28:30 – Iranian roots in Aberdeen00:38:15 – Foundation year in London00:40:55 – Outdoor pursuits and Ironman training00:46:10 – CBCT and safe-ended files00:50:05 – Endo, implants and aesthetics under one roof00:52:00 – Treatment coordinators and ethical selling00:57:15 – The value of mentorship00:59:00 – Networking and landing the jobs01:02:55 – The two practices compared01:07:35 – Lucas Lassman and the most inspiring lecture01:10:40 – Dental resources: YouTube and Instagram01:15:10 – Being Mortal and Man's Search for Meaning01:16:30 – Modern Wisdom and guilty pleasures01:22:35 – Ten-year plan01:27:40 – Fantasy dinner partyAbout Ali HashemizadehAli Hashemizadeh is a 27-year-old private associate dentist working across two practices in the northeast of England — Middleton Saint George Dental in Darlington and Ken Harris's clinic in Sunderland — where he has developed a particular focus on endodontics. Born and raised in Aberdeen to Iranian parents, he qualified from Newcastle University and completed his foundation year in London before heading back north.

How teachers and students are using AI at school and beyond. About John Dolman John Dolman is a Media Studies teacher at Ponteland Community High School. He holds an MEd in Educational Leadership and Practitioner Enquiry and a Postgraduate Certificate in Education from Newcastle University. He has worked in schools in the UK, Malaysia and the United Arab Emirates, teaching English and Media and holding leadership roles including Head of Languages and Cultures and Raising Achievement Deputy. His responsibilities have included curriculum development, teacher training and mentoring, data analysis, and performance management. He is interested in using AI and generative AI in practical ways to support teaching and learning. Outside of work, he enjoys the outdoors, practises martial arts, and cares about the environment and his local community. LinkedIn: https://www.linkedin.com/in/john-dolman-3836b8251/  Resources https://theaienglishteacher.wordpress.com/  https://activelyintelligent.org/about John Mikton on Social Media LinkedIn: https://www.linkedin.com/in/jmikton/ Twitter: https://twitter.com/jmikton Web: beyonddigital.org Dan Taylor on social media: LinkedIn: https://www.linkedin.com/in/appsevents  Twitter: https://twitter.com/appdkt  Web: www.appsevents.com Listen on: iTunes / Podbean / Stitcher / Spotify / YouTube Do a full security audit of your Workspace for free at https://workspaceaudit.com Would you like to have a free 1 month trial of the new Google Workspace Plus (formerly G Suite Enterprise for Education)? Just fill out this form and we'll get you set up bit.ly/GSEFE-Trial

Join Dr. Siobhan McCormack as she welcomes one of the top early-life microbiome scientists in the field, Professor Chris Stewart. Discover the origins of your gut microbiome, the biological superpowers of breast milk, and how lab-grown "organoids" are uncovering surprising ways to protect preterm babies.What We Cover:The Genesis of You: How birth mode and early feeding shape our microbial foundations.Inside the Stewart Lab: Using lab-grown human "organoids" to study host-microbe interactions in real-time.The Magic of HMOs: Why mothers produce complex sugars (Human Milk Oligosaccharides) that feed gut microbes instead of the baby.The "Good" Clostridium: Groundbreaking research on a specific Clostridium perfringens strain that thrives on HMOs to protect preterm infants from gut diseases.Probiotics & Preemies: Navigating FDA regulations and the future of personalized medicine in neonatal care.About Professor Stewart leads human microbiome research at Newcastle University. His lab combines computational biology with innovative wet-lab human organoid models to study global health issues, focusing primarily on the early-life gut microbiome and protecting vulnerable infants.Connect with the Stewart Lab:Newcastle University ProfileGoogle ScholarTwitterNewcastle Neonatal Nutrition and NEC Research (N4)Scientific References & Further Reading:Stewart CJ, et al. (2018). Temporal development of the gut microbiome in early childhood from the TEDDY study. Nature, 562(7728):583–8.Chapman JA, et al. (2026). Clostridia from preterm infants metabolize human milk oligosaccharides to suppress pathobionts and modulate intestinal function in organoids. Nat Microbiol, 1–20.Masi AC, et al. (2021). Human milk oligosaccharide DSLNT and gut microbiome in preterm infants predicts necrotising enterocolitis. Gut, 70(12):2273–82.Beck LC, et al. (2022). Strain-specific impacts of probiotics are a significant driver of gut microbiome development in very preterm infants. Nat Microbiol, 7(10):1525–35.UNICEF UK: Breastfeeding in the UKThis podcast is brought to you in collaboration with the British Society of Lifestyle Medicine.Disclaimer:The content in this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your doctor or qualified healthcare provider. Never disregard professional medical advice or delay in seeking it because of something you have heard on this podcast.

It's time for another BIG and BRILLIANT adventure into the world of science on this week’s Science Quest! In Science in the News, humans have travelled further into space than ever before as Artemis II orbits the Moon, scientists achieve a world first by mapping the DNA of a monkey, and Richard Wall from the University of Bristol joins Dan to explain the spread of a dangerous flesh-eating fly and why experts are keeping a close eye on it. It’s time for your questions too. Ryan wants to know why Earth spins on a wonky axis, and Brian Diffey from Newcastle University explains how your body makes vitamin D from sunlight. Dangerous Dan introduces the secretary bird, a fierce and fascinating hunter with a very unusual way of catching its prey. Then it’s time for Brain Box, where Dan’s high-tech question chamber puts top scientists to the test. This week, analytical chemist Kirsty Penkham takes on the challenge. Plus, in Kitchen Chemistry, K-Mistry explores the science of solids, liquids and gases, turning your kitchen into a chemistry lab. From deep space missions to DNA discoveries and dangerous insects, this episode is packed with brilliant science. What we learn about: • NASA’s Artemis II mission and its journey around the Moon• A world-first breakthrough in mapping monkey DNA• The threat of a flesh-eating fly• Why Earth spins on a tilted axis• How the body makes vitamin D from sunlight• The hunting skills of the secretary bird• The science of solids, liquids and gases All that and more on this week’s Science Quest!Join Fun Kids Podcasts+: https://funkidslive.com/plusSee omnystudio.com/listener for privacy information.

John Wilson onRobert Fox the producer who had a career that spanned theatre, film and television. We have tributes from Colin Firth, Rupert Everett and Robert's brother, the actor Edward Fox.Mary Rand MBE, the first British woman to win an Olympic athletics gold medal at the 1964 Tokyo Olympic Games.Sir Tony Hoare, one of the world's leading computer software designers who developed algorithms and languages which have become industry standards. Biruté Galdikas, the primatologist and conservationist whose years of studying orangutans in their natural habitat helped understand and protect the primates.Interviewee: Edward Fox Interviewee: Rupert Everett Interviewee: Colin Firth Interviewee: Wendy Sly Interviewee: Professor Bill Roscoe Interviewee: Professor Erin VogelProducer: Gareth Nelson-Davies Assistant Producer: Ribika Moktan Researcher: Jesse Edwards Editor: Glyn TansleyArchive used: Another Country movie promo, Another Country Trailer, 1984, director Marek Kanievska, writer Julian Mitchell, Goldcrest Films International,, YouTube Uploaded by Sundance Now, 04/10/2017; Another Country, Queen's Theatre, directed by Stuart Burge, written by Julian Mitchell, 1982, broadcast on Newsnight, BBC Two, 02/03/1982; Mary Rand at the 1964 Olympics, BBC Sound Archive, commentary by David Coleman, 1964 Tokyo Olympics, 14/01/1964; An Interview with Tony Hoare, ACM 1980 A.M. Turing Award Recipient, Interviewer: Cliff Jones, Newcastle University, 24/11/2015, uploaded to Association for Computing Machinery (ACM) YouTube channel on 25/10/2016; Biruté Galdikas interview, Good Morning, BBC One, 15/02/1995; Biruté Galdikas, Great Apes Documentary, BBC Two, 29/02/1976; Biruté Galdikas interview, Woman's Hour, BBC Radio 4, 16/02/1995;

KTRA 2025 Album (Ltd Ed USB Cassette) >>GRAB IT HEREGRAB IT HERE

New research suggests there's a simple way to get students match fit; let them wear sports gear all day rather than traditional uniforms. A study in collaboraton with Australia's Newcastle University found out of thousands of responses, more than three quarters supported the daily wearing of activity enabling sports uniforms. Newcastle University's Belinda Peden spoke to Lisa Owen.

With the war in Iran leading to the closure of the Strait of Hormuz, preventing or restricting oil and gas being exported from many of the Gulf states, the UK's energy policy has come to the fore once more. Proponents of renewables claim that a rapid shift to homegrown wind and solar power will spare us from the volatility of international supplies of fossil fuels. Critics argue the UK will need oil and gas for decades to come, but we can produce more, either in the North Sea or by fracking on land. This debate from the Battle of Ideas festival 2025 is, therefore, highly topical. Where should future energy policy go? ORIGINAL FESTIVAL INTRODUCTION In June 2019, the Conservative government amended the Climate Change Act to insert a target of ‘net zero' emissions by 2050. At the 2024 General Election, all the major political parties, with the exception of Reform, promised to back the goal, with any differences being about when to implement various policies, such as gas-boiler and petrol-car bans. Reform is well ahead in the opinion polls, and calling for the end of Net Zero and the resumption of fracking. Conservative leader Kemi Badenoch has said: ‘We've got to stop pretending to the next generation… Net Zero by 2050 is impossible.' Is Net Zero gradually being ditched? For proponents of the policy, climate change remains a clear and present danger. The energy and climate change secretary, Ed Miliband declared in May that Keir Starmer and Rachel Reeves are still backing Net Zero: ‘It's absolutely central to their economic growth and energy security, as well as climate agenda … So as far as I'm concerned, they are 100% committed to this agenda.' Labour has stopped new licences for gas and oil production in the North Sea and is committed to expanding renewable energy, with Miliband claiming: ‘People recognise that cheap, clean renewables beat expensive, insecure fossil fuels.' But fuel bills haven't fallen as the gas-price crisis of 2022 has faded. UK energy prices remain high by international standards, despite (or because of) the expansion of renewables, something highlighted by the need to rescue Scunthorpe steelworks. In June, it was reported that the government was planning to subsidise energy costs for energy-intensive industries. Sky News reported that in 2023, British businesses paid £258 per megawatt-hour for electricity compared to £178 in France and £177 in Germany, according to International Energy Agency data. Will the Net Zero consensus break down further – and should it? At a time when China's greenhouse gas emissions dwarf those of the UK and are still rising, does it make economic or environmental sense to decarbonise? Or does the threat of climate change demand that the UK takes a lead and we accept lower living standards to save the planet? SPEAKERS Jonny Ball contributing editor, UnHerd Dr Caspar Hewett lecturer, School of Engineering, Newcastle University; co-director, NERC FLOOD-CDT; director, The Great Debate Ruari McCallion freelance writer Ali Miraj broadcaster; founder, the Contrarian Prize; infrastructure financier; DJ Kathryn Porter consultant, Watt-Logic CHAIR Austin Williams director, Future Cities Project; honorary research fellow, XJTLU, Suzhou, China; author, China's Urban Revolution

Allen covers a week of offshore wind milestones including the Maersk Viridis sailing toward New York, Revolution Wind’s first power delivery, Vineyard Wind’s final blade, RWE’s Thor project in Denmark, and Kinewell Energy’s fundraise in England. Sign up now for Uptime Tech News, our weekly newsletter on all things wind technology. This episode is sponsored by Weather Guard Lightning Tech. Learn more about Weather Guard’s StrikeTape Wind Turbine LPS retrofit. Follow the show on YouTube, Linkedin and visit Weather Guard on the web. And subscribe to Rosemary’s “Engineering with Rosie” YouTube channel here. Have a question we can answer on the show? Email us! Good morning, everyone. There is a ship sailing toward America right now. And when it arrives, it will be the most powerful wind turbine installation vessel ever to work in United States waters. Her name is Maersk Viridis. Built by Seatrium in Singapore. Forty thousand tonnes of steel. A main crane reaching one hundred and eighty meters into the sky. Designed to lift the next generation of fifteen-megawatt turbines. At her naming ceremony, godmother Charlotte Norkjer Larsen smashed a bottle of champagne against the main crane pedestal. Viridis — the Latin word for green. The Viridis is headed for Equinor’s Empire Wind project off the coast of New York. When complete, five hundred thousand homes will have power. Now, there is something worth noting. This vessel was built as a Jones Act-compliant solution. That means it can work legally in United States offshore waters. It was built with zero lost time injuries. And while one great ship sails west, the wind industry is moving forward on every front. In New England, the Revolution Wind project delivered its first power to the grid. Seven hundred and four megawatts. Power enough for up to three hundred and fifty thousand homes. Built by local union workers logging more than two million hours. That same week, workers installed the last turbine blade on Vineyard Wind. A project that endured a fractured blade in July of twenty twenty-four, a legal battle to survive a federal stop-work order, and came out the other side — still standing. On the other side of the world, Denmark is doing what Denmark does. The first turbine is now installed at the Thor offshore wind project. In the North Sea, off the west coast of Jutland. When finished, Thor will be Denmark’s largest offshore wind farm. Seventy-two turbines. Each capable of fifteen megawatts. Each turbine rising one hundred and forty-eight meters above the sea. Total project capacity — one-point-one gigawatts. The installation vessel is the Brave Tern, operated by Fred. Olsen Windcarrier. She carries three turbines per trip. Some blades on Thor are recyclable. That is not a headline you could have written ten years ago. And the developer building Thor? That would be RWE. RWE is everywhere right now. Now, for a small story with a large idea behind it. In Wallsend, England, a twelve-person company called Kinewell just raised seven hundred and fifty thousand pounds. Founded by an engineer named Andrew Jenkins while he was earning his PhD at Newcastle University. Kinewell builds software — software that optimises the design of offshore wind farms. Cable layouts, turbine placement, transmission systems. All three, working together. Their clients include Equinor, SSE Renewables, and Eurus Energy. The new funding unlocks a further six-figure grant, bringing total new capital to more than one million pounds. Ten new jobs in the next six months. Their software has saved clients hundreds of millions of pounds. That is what the right tool can do. So let us step back and look at the week. A ship christened and sailing to New York. A New England grid receiving its first offshore wind power. Vineyard Wind — finished at last. Denmark’s largest wind farm, growing turbine by turbine. And a twelve-person software firm in northeast England, helping shape the invisible architecture of the energy transition. That is the Wind Energy News for the 16th of March, 2026. Join us for the Uptime Wind Energy podcast tomorrow.

Johnny Mac shares five good news stories: In Texas, Sean enlisted an entire preschool class to surprise his fiancée Zoey with a bridal shower; the couple had attended the school at age four and reconnected at a 2021 summer camp. New research from Newcastle University suggests a single 10-minute high-intensity cycling session can quickly change blood molecules, increasing 13 proteins including one tied to DNA repair, potentially helping suppress cancer growth in overweight but otherwise healthy adults aged 50–78. In England, Mark and Carol spent three decades and tens of thousands restoring a closed 1950 train station into “The Old Station,” now open for visits and overnight stays. In the Mediterranean, Cyprus is fighting invasive lionfish by serving it in restaurants. British veteran Hari became the first above-the-knee double amputee to climb the highest mountain on every continent.John also hosts Daily Comedy NewsUnlock an ad-free podcast experience with Caloroga Shark Media!  For Apple users, hit the banner which says Uninterrupted Listening on your Apple podcasts app. Subscribe now for exclusive shows like 'Palace Intrigue,' and get bonus content from Deep Crown (our exclusive Palace Insider!) Or get 'Daily Comedy News,' and '5 Good News Stories' with no commercials! Plans start at $4.99 per month, or save 20% with a yearly plan at $49.99. Join today and help support the show!Get more info from Caloroga Shark Media and if you have any comments, suggestions, or just want to get in touch our email is info@caloroga.com

In this episode, Jim Keane, and Newcastle University mental health advisor Liam Snaith explore how Jisc learning analytics is transforming student support. Liam explains how engagement and attendance data such as VLE activity and in‑person participation helps wellbeing staff quickly identify students who may be struggling, guide sensitive conversations and make informed decisions about interventions. They discuss how having a single, accessible view of student engagement reduces delays, supports decision making and enables more consistent, proactive support across the university. Watch the episode on YouTube Show notes Discover more about Jisc learning analytics Access the Newcastle University Health and Wellbeing Service website View the Newcastle University 24/7 support site Subscribe to Headlines - our newsletter which has all the latest edtech news, guidance and events tailored to you

In this episode of the Dementia Research Podcast, host Dr Gemma Lace is joined by guests, Dr Eric Hill from Loughborough University, Kalliopi Mavromati from University of Glasgow, Natalie Wickett from Simon Fraser University and Dr Kate Harris from Newcastle University. Together they discuss the intersection of ADHD and research, exploring personal experiences, misconceptions, and coping strategies. The conversation highlights the unique challenges faced by researchers with ADHD, the importance of understanding and empathy in academic settings, and the various ways individuals navigate their symptoms. The discussion also touches on the role of medication and the need for tailored approaches to support neurodiverse individuals in academia. -- A transcript of this show, links and show notes and profile on all our guests are available on our website at https://www.dementiaresearcher.nihr.ac.uk -- Follow us on social media: https://www.instagram.com/dementia_researcher/ https://www.facebook.com/Dementia.Researcher/ https://www.twitter.com/demrescommunity https://www.linkedin.com/company/dementia-researcher https://www.bsky.app/profile/dementiare…archer.bsky.social -- Download and Register with our Community App: https://www.onelink.to/dementiaresearcher -- Chapters 00:00 Introduction to ADHD in Research 02:56 Understanding ADHD: Definitions and Misconceptions 06:55 Personal Experiences of ADHD 10:37 Hyperfocus: The Double-Edged Sword 14:22 Gender Differences in ADHD Presentation 21:46 ADHD in Academia: Challenges and Realizations 25:35 The Positive Aspects of ADHD 29:11 Coping Mechanisms and Strategies 34:10 Medication: The Good, The Bad, and The Necessary 48:14 Final Thoughts and Key Takeaways

On this edition of The Media Show, Ros Atkins examines the continuing public interest in the Lucy Letby case, as a new Netflix documentary reaches the top of the UK viewing rankings. He speaks to Josh Halliday, North of England Editor at The Guardian, and Dr Bethany Usher of Newcastle University, whose work focuses on the ethics of true‑crime storytelling and the development of new guidelines for the genre.Tom Freston, co‑founder of MTV, reflects on how the channel's launch in 1981 transformed popular culture and what its closure in the UK and Europe signifies for its legacy.And we assess the state of the advertising industry following one of its most challenging years on record. James Kirkham, founder of Iconic, discusses his view that the traditional agency model is in steep decline, while Becky Owen, Chief Marketing Officer at Billion Dollar Boy, outlines the rapid expansion of influencer marketing and the new dynamics shaping the sector.Producer: Lisa Jenkinson

Max Pearson presents a collection of the week's Witness History interviews from the BBC World Service.We travel back to Chile in 2006 where more than 600,000 schoolchildren are marching through the streets to protest about their schools. The nationwide demonstrations will become known as the "Penguin Revolution".Our guest Dr Laura Tisdall, a historian from Newcastle University, explains why this isn't the first time children have challenged authority.And we examine another protest in Kaohsiung, Taiwan, in 1979 which became a seminal moment in the country's transition to democracy.Plus, one of the most defining moments of World War Two – the liberation of Auschwitz, the Nazis' largest death camp in 1945.And the remarkable story of the 5,000-year-old mummy found frozen and perfectly preserved in Europe's Ötzal Alps in 1991. In sport, we explore the inspiring story of how rugby union came to thrive in Syria - despite mass protests and violent government crackdowns during 2011...Finally, we celebrate 100 years since a technological breakthrough that would change the world. The start of television.Contributors:Karina Delfino – one of the leaders of the Penguin Revolution.Dr Laura Tisdall - lecturer in Modern British History, Newcastle University.Yao Chia-wen – protester in the Kaohsiung Incident.General Vasily Petrenko – Soviet army commander who helped liberate Auschwitz. Konrad Spindler – archaeologist.Rainer Henn - forensic pathologist.Mohamad Jarkou – Syrian rugby union player.Iain Logie Baird – grandson of John Logie Baird, the inventor of television.(Photo: High school students in Santiago, 2006. Credit: Claudio Pozo/AFP via Getty Images)

JC Penet, Reader in Translation Industry Studies at Newcastle University, and Joss Moorkens, Associate Professor at DCU, join SlatorPod to talk about the new open-access book Teaching translation in the age of generative AI: New paradigm, new learning?The duo explains how large language models (LLMs) have a different impact than earlier machine translation breakthroughs as they generate human-like text, respond to prompts, and adapt output to context. Public hype around LLMs has affected demand for some translators and fueled misconceptions around the value of studying translation. Although, JC and Joss stress that translation education must adapt.JC outlines how students need to assess whether output is appropriate for purpose, audience, risk, and context. This places greater importance on skills such as selection, evaluation, and effective prompting, while still relying on core linguistic and cultural competence.Joss adds that this shift reflects real industry practice, where different content types already receive different levels of automation and human involvement. Drawing on healthcare research, he highlights how AI can outperform traditional workflows in some contexts but fail badly in others, especially across languages with uneven data coverage.Joss also highlights ethical blind spots that arise when performance metrics dominate decision-making. He describes a “triple bottom line” approach that weighs people, planet, and performance equally.On fears of de-skilling, JC argues that excluding AI from classrooms poses a greater risk. Without guided engagement, students may use tools uncritically or fail to develop AI literacy altogether. Joss points to initiatives such as LT-LiDER, an Erasmus+ project designed to build AI literacy among educators.Looking ahead, the duo contends that studying languages and translation remains valuable because it develops deep reading, critical thinking, intercultural awareness, and adaptability.

Our contemporary world is inescapably Greek. Whether in a word like “pandemic,” a Freudian state of mind like the “Oedipus complex,” or a replica of the Parthenon in a Chinese theme park, ancient Greek culture shapes the contours of our lives. Ever since the first Roman imitators, we have been continually falling under the Greeks' spell. But how did ancient Greece spread its influence so far and wide? And how has this influence changed us? In What the Greeks Did for Us (Yale UP, 2023), Tony Spawforth explores our classical heritage, wherever it's to be found. He reveals its legacy in everything from religion to popular culture, and unearths the darker side of Greek influence—from the Nazis' obsession with Spartan “racial purity” to the elitism of classical education. Paying attention to the huge breadth and variety of Hellenic influence, this book paints an essential portrait of the ancient world's living legacy—considering to whom it matters, and why. Tony Spawforth is emeritus professor of ancient history at Newcastle University. As well as leading cultural tours in Greece, he has presented eight documentaries for the BBC and has published thirteen books, including The Story of Greece and Rome. Morteza Hajizadeh is a Ph.D. graduate in English from the University of Auckland in New Zealand. His research interests are Cultural Studies; Critical Theory; Environmental History; Medieval (Intellectual) History; Gothic Studies; 18th and 19th Century British Literature. YouTube channel. Twitter. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/intellectual-history

Noninterventional studies in clinical research are underutilized in clinical research and inefficient. Dan Drozd, CMO of PicnicHealth, knows we can do better. With host Deborah Borfitz, Drozd discusses the issues and ramifications researchers face from the lack of noninterventional studies, offers tactics for raising the bar for evidence generation, and shares what he expects in the clinical research space in 2026 in this episode of the Scope of Things. Plus, Borfitz shares the latest news on an expanding good pharma score card, an entirely telehealth-based cancer trial, a novel online platform for bowel cancer research, improving patient-reported outcomes in cancer trials, a virtual clinical trial for psychedelics, and identifying Type 1 diabetes in the symptom-less window stage. Show Notes   News Roundup Good Pharma Scorecard Study in JAMA Internal Medicine News on the Yale Scool of Medicine website  Nationwide telehealth trial for cancer News on The Ohio State University website Online platform for bowel cancer research News on the Newcastle University website Patient-reported outcomes in cancer clinical trials Paper in The Lancet Oncology News on the European Organisation for Research and Treatment of Cancer website Virtual clinical trial of psychedelics Research article in Advanced Science Type 1 diabetes risk prediction testing Study in The Lancet News on the University of Exeter website Guest Dan Drozd, M.D., CMO of PicnicHealth The Scope of Things podcast explores clinical research and its possibilities, promise, and pitfalls. Clinical Research News senior writer, Deborah Borfitz, welcomes guests who are visionaries closest to the topics, but who can still see past their piece of the puzzle. Focusing on game-changing trends and out-of-the-box operational approaches in the clinical research field, the Scope of Things podcast is your no-nonsense, insider's look at clinical research today.

Our contemporary world is inescapably Greek. Whether in a word like “pandemic,” a Freudian state of mind like the “Oedipus complex,” or a replica of the Parthenon in a Chinese theme park, ancient Greek culture shapes the contours of our lives. Ever since the first Roman imitators, we have been continually falling under the Greeks' spell. But how did ancient Greece spread its influence so far and wide? And how has this influence changed us? In What the Greeks Did for Us (Yale UP, 2023), Tony Spawforth explores our classical heritage, wherever it's to be found. He reveals its legacy in everything from religion to popular culture, and unearths the darker side of Greek influence—from the Nazis' obsession with Spartan “racial purity” to the elitism of classical education. Paying attention to the huge breadth and variety of Hellenic influence, this book paints an essential portrait of the ancient world's living legacy—considering to whom it matters, and why. Tony Spawforth is emeritus professor of ancient history at Newcastle University. As well as leading cultural tours in Greece, he has presented eight documentaries for the BBC and has published thirteen books, including The Story of Greece and Rome. Morteza Hajizadeh is a Ph.D. graduate in English from the University of Auckland in New Zealand. His research interests are Cultural Studies; Critical Theory; Environmental History; Medieval (Intellectual) History; Gothic Studies; 18th and 19th Century British Literature. YouTube channel. Twitter. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/new-books-network

Our contemporary world is inescapably Greek. Whether in a word like “pandemic,” a Freudian state of mind like the “Oedipus complex,” or a replica of the Parthenon in a Chinese theme park, ancient Greek culture shapes the contours of our lives. Ever since the first Roman imitators, we have been continually falling under the Greeks' spell. But how did ancient Greece spread its influence so far and wide? And how has this influence changed us? In What the Greeks Did for Us (Yale UP, 2023), Tony Spawforth explores our classical heritage, wherever it's to be found. He reveals its legacy in everything from religion to popular culture, and unearths the darker side of Greek influence—from the Nazis' obsession with Spartan “racial purity” to the elitism of classical education. Paying attention to the huge breadth and variety of Hellenic influence, this book paints an essential portrait of the ancient world's living legacy—considering to whom it matters, and why. Tony Spawforth is emeritus professor of ancient history at Newcastle University. As well as leading cultural tours in Greece, he has presented eight documentaries for the BBC and has published thirteen books, including The Story of Greece and Rome. Morteza Hajizadeh is a Ph.D. graduate in English from the University of Auckland in New Zealand. His research interests are Cultural Studies; Critical Theory; Environmental History; Medieval (Intellectual) History; Gothic Studies; 18th and 19th Century British Literature. YouTube channel. Twitter. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/literary-studies

Our contemporary world is inescapably Greek. Whether in a word like “pandemic,” a Freudian state of mind like the “Oedipus complex,” or a replica of the Parthenon in a Chinese theme park, ancient Greek culture shapes the contours of our lives. Ever since the first Roman imitators, we have been continually falling under the Greeks' spell. But how did ancient Greece spread its influence so far and wide? And how has this influence changed us? In What the Greeks Did for Us (Yale UP, 2023), Tony Spawforth explores our classical heritage, wherever it's to be found. He reveals its legacy in everything from religion to popular culture, and unearths the darker side of Greek influence—from the Nazis' obsession with Spartan “racial purity” to the elitism of classical education. Paying attention to the huge breadth and variety of Hellenic influence, this book paints an essential portrait of the ancient world's living legacy—considering to whom it matters, and why. Tony Spawforth is emeritus professor of ancient history at Newcastle University. As well as leading cultural tours in Greece, he has presented eight documentaries for the BBC and has published thirteen books, including The Story of Greece and Rome. Morteza Hajizadeh is a Ph.D. graduate in English from the University of Auckland in New Zealand. His research interests are Cultural Studies; Critical Theory; Environmental History; Medieval (Intellectual) History; Gothic Studies; 18th and 19th Century British Literature. YouTube channel. Twitter. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/art

Taylor Swift's Eras Tour shattered records, becoming the highest-grossing concert tour of all time, redefining what's possible and confirming a new era in the business of touring. As streaming transformed how we listen to music, selling records is no longer the financial centrepiece it once was for artists. Instead, exclusivity has been transferred to the live experience. But staging shows on this scale requires enormous investment and complex production. At the same time, ticket scarcity fuels extraordinary demand and rising prices, which mean big ticket prices.Tanya Beckett explores how technology, fandom and economics turn modern concert tours into multi-billion-dollar ventures.This week on The Inquiry, we're asking: How did music megatours become such a money spinner?Contributors Kevin Kim, Head of Asia at music distribution company Route Note, Seoul, South KoreaSerona Elton, professor at the Frost School of Music at the University of Miami, United StatesAdam Behr, Reader and Head of Music at Newcastle University, United KingdomPoppy Reid, music journalist and founder of Curious Media, Sydney, AustraliaPresenter: Tanya Beckett Producers: Maeve Schaffer and Matt Toulson Researcher: Evie Yabsley Production Management Assistant: Liam Morrey Technical Producer: Craig Boardman Editor: Tom Bigwood(Photo: Taylor Swift during The Eras Tour. Credit: Erika Goldring/TAS24/Getty Images)

In this episode of the Leading Voices in Food podcast, Norbert Wilson of Duke University's Sanford School of Public Policy speaks with researchers Jean Adams from the University of Cambridge and Mike Essman from Duke's World Food Policy Center. They discuss the mandatory calorie labeling policy introduced in England in April 2022 for large food-away-from-home outlets. The conversation covers the study recently published in the British Medical Journal, exploring its results, strengths, limitations, and implications within the broader context of food labeling and public health policies. Key findings include a slight overall reduction in calorie content offered by food outlets, driven by the removal of higher-calorie items rather than reformulation. The discussion also touches on the potential impacts on different consumer groups, the challenges of policy enforcement, and how such policies could be improved to more effectively support public health goals. Interview Summary Now everyone knows eating out is just part of life. For many, it's a place to make connections, can be a guilty pleasure, and sometimes it's just an outright necessity for busy folks. But it is also linked to poor dietary quality, weight gain, and even obesity. For policymakers, the challenge is identifying what policy changes can help improve population health. Jean, let's begin with you. Can you tell our listeners about the UK's menu labeling intervention and what change did you hope to see? Jean - Yes, so this was a policy that was actually a really long time in coming and came in and out of favor with a number of different governments. So maybe over the last 10 years we've had various different suggestions to have voluntary and/or mandatory calorie labeling in the out-of-home sector. Eventually in April, 2022, we did have new mandatory regulations that came into a force that required large businesses just in England - so not across the whole of the UK, just in England - if they sold food and non-alcoholic drinks and they had to display the calories per portion of every item that they were selling. And then have alongside that somewhere on their menu, a statement that said that adults need around 2000 calories per day. The policy applied just to large businesses, and the definition of that was that those businesses have 250 or more employees, but the employees didn't all have to be involved in serving food and drinks. This might apply also to a large hotel chain who just have some bars or something in their hotels. And the food and drinks covered were things that were available for immediate consumption. Not prepackaged. And then there was also this proviso to allow high-end restaurants to be changing their menus regularly. So, it was only for things that were on the menu for at least 30 days. You mentioned that this policy or a menu labeling might have at least two potential modes of impacts. There's first this idea that providing calories or any sort of labeling on food can somehow provide information for consumers to make what we might hope would be better choices. Might help them choose lower calorie options or healthier options. And then the second potential impact is that businesses might also use the information to change what sort of foods they're serving. It might be that they didn't realize how many calories were in the foods and they're suddenly embarrassed about it. Or as soon as their customers realize, they start to put a little bit of pressure on, you know, we want something a little bit lower calorie. So, there's this potential mechanism that operates at the demand side of how consumers might make choices. And another one at the supply side of what might be available to consumers. And we knew from previous evaluations of these sorts of interventions that there was some evidence that both could occur. Generally, it seems to be that findings from other places and countries are maybe null to small. So, we were thinking that maybe we might see something similar in England. Thank you for sharing that background. I do have a question about the length of time it took to get this menu labeling law in place. Before we get into the results, do you have a sense of why did it take so long? Was it industry pushback? Was it just change of governments? Do you have a sense of that? Jean - Yes, so I think it's probably a bit of both. To begin with, it was first proposed as a voluntary measure actually by industry. So, we had this kind of big public-private partnership. What can industry do to support health? And that was one of the things they proposed. And then they didn't really do it very well. So, there was this idea that everybody would do it. And in fact, we found maybe only about 20% of outlets did it. And then definitely we have had government churn in the UK over the last five years or so. So, every new prime minister really came in and wanted to have their own obesity policy threw out the last one started over. And every policy needs consulted on with the public and then with industry. And that whole process just kind of got derailed over and over again. Thank you. That is really helpful to understand that development of the policy and why it took time. Industry regulated policy can be a tricky one to actually see the results that we would hope. You've already given us a sort of insight into what you thought the results may be from previous studies - null to relatively small. So, Mike, I want to turn to you. Can you tell us what came out of the data? Mike - Thank you, yes. So, we found a small overall drop in average calories offered per item. That amounts to a total of nine calories per item reduction in our post policy period relative to pre policy. And this is about a 2% reduction. It was statistically significant and we do in public health talk about how small effects can still have big impacts. So, I do want to sort of put that out there, but also recognize that it was a small overall drop in calories. And then what we did is we looked at how different food groups changed, and also how calories changed at different types of restaurants, whether it was fast food, restaurants, sit downs that we call pubs, bars, and inns. And then also other different types of takeaways like cafes and things like that where you might get a coffee or a cappuccino or something like that. What we found was driving the overall reduction in calories was a reduction in higher calorie items. So, as Jean mentioned at the outset, one of the things we were trying to identify in this analysis was whether we saw any evidence of reformulation. And we defined reformulation as whether specific products were reduced in their calories so that the same products were lower calories in the post period. We define that as reformulation. And that would be different from, say, a change in menu offering where you might identify a high calorie item and take it off the menu so that then the overall calories offered goes down on average. We found more evidence for the latter. Higher calorie items were removed. We separated into categories of removed items, items that were present in both periods, and new items added in the post period. There were higher calorie items in the removed group. The items that were present in both periods did not change. The new items were lower calorie items. What this says overall is this average reduction is driven by taking off high calorie items, adding some slightly lower calorie items. But we did not find evidence for reformulation, which is a crucial finding as well. We saw that the largest reductions occurred in burgers, beverages and a rather large mixed group called Mains. So, burgers reduced by 103 calories per item. That's pretty substantial. One of the reasons that's so large is that burgers, particularly if they're offered at a pub and might even come with fries or chips, as they say in the UK. And because they have such a high baseline calorie level, there's more opportunity to reduce. So, whether it's making it slightly smaller patty or reducing the cheese or something like that, that's where we saw larger reductions among the burgers. With beverages, typically, this involved the addition of lower calorie options, which is important if it gives an opportunity for lower calorie selections. And that was the main driver of reduction there. And then also we saw in Mains a reduction of 30 calories per item. A couple of the other things we wanted to identify is whether there was a change in the number of items that were considered over England's recommended calories per meal. The recommended calories per meal is 600 calories or less for lunch and dinner. And we saw no statistical change in that group. So overall, we do see a slight reduction in average calories. But this study did not examine changes in consumer behavior. I do want to just briefly touch on that because this was part of a larger evaluation. Another study that was published using customer surveys that was published in Nature Human Behavior found no change in the average calories purchased or consumed after the policy. This evaluation was looking at both the supply and the demand side changes as a result of this policy. Thanks, Mike and I've got lots of questions to follow up, but I'll try to control myself. The first one I'm interested to understand is you talk about the importance of the really calorie-heavy items being removed and the introduction of newer, lower calorie items. And you said that this is not a study of the demand, but I'm interested to know, do you have a sense that the higher calorie items may not have been high or top sellers. It could be easy for a restaurant to get rid of those. Do you have any sense of, you know, the types of items that were removed and of the consumer demand for those items? Mike - Yes. So, as I mentioned, given that the largest changes were occurring among burgers, we're sort of doing this triangulation attempt to examine all of the different potential impacts we can with the study tools we have. We did not see those changes reflected in consumer purchases. So, I think sticking with the evidence, the best thing we could say is that the most frequently purchased items were not the ones that were being pulled off of menus. I think that would be the closest to the evidence. Now, no study is perfect and we did in that customer survey examine the purchases and consumption of about 3000 individuals before and after the policy. It's relatively large, but certainly not fully comprehensive. But based on what we were able to find, it would seem that those reductions in large calorie items, it's probably fair to say, were sort of marginal choices. So, we see some reduction in calories at the margins. That's why the overall is down, but we don't see at the most commonly sold. I should also mention in response to that, a lot of times when we think about eating out of home, we often think about fast food. We did not see reductions in fast food chains at all, essentially. And so really the largest reductions we found were in what would be considered more sit-down dining establishment. For example, sit-down restaurants or even pubs, bars and ends was one of our other categories. We did see average reductions in those chains. The areas you kind of think about for people grabbing food quickly on the go, we did not see reductions there. And we think some of this is a function of the data itself, which is pubs, bars and inns, because they offer larger plates, there's a little bit more space for them to reduce. And so those are where we saw the reductions. But in what we might typically think is sort of the grab and go type of food, we did not see reductions in those items. And so when we did our customer surveys, we saw that those did not lead to reductions in calories consumed. Ahh, I see this and thank you for this. It sounds like the portfolio adjusted: getting rid of those heavy calorie items, adding more of the lower calorie items that may not have actually changed what consumers actually eat. Because the ones that they typically eat didn't change at all. And I would imagine from what you've said that large global brands may not have made many changes, but more local brands have more flexibility is my assumption of that. So that, that's really helpful to see. As you all looked at the literature, you had the knowledge that previous studies have found relatively small changes. Could you tell us about what this work looks like globally? There are other countries that have tried policy similar to this. What did you learn from those other countries about menu labeling? Jean - Well, I mean, I'm tempted to say that we maybe should have learned that this wasn't the sort of policy that we could expect to make a big change. To me one of the really attractive features of a labeling policy is it kind of reflects back those two mechanisms we've talked about - information and reformulation or changing menus. Because we can talk about it in those two different ways of changing the environment and also helping consumers make better choices, then it can be very attractive across the political landscape. And I suspect that that is one of the things that the UK or England learned. And that's reflected in the fact that it took a little while to get it over the line, but that lots of different governments came back to it. That it's attractive to people thinking about food and thinking about how we can support people to eat better in kind of a range of different ways. I think what we learned, like putting the literature all together, is this sort of policy might have some small effects. It's not going to be the thing that kind of changes the dial on diet related diseases. But that it might well be part of an integrated strategy of many different tools together. I think we can also learn from the literature on labeling in the grocery sector where there's been much more exploration of different types of labeling. Whether colors work, whether black stop signs are more effective. And that leads us to conclusions that these more interpretive labels can lead to bigger impacts and consumer choices than just a number, right? A number is quite difficult to make some sense of. And I think that there are some ways that we could think about optimizing the policy in England before kind of writing it off as not effective. Thank you. I think what you're saying is it worked, but it works maybe in the context of other policies, is that a fair assessment? Jean - Well, I mean, the summary of our findings, Mike's touched on quite a lot of it. We found that there was an increase in outlets adhering to the policy. That went from about 20% offered any labeling to about 80%. So, there were still some places that were not doing what they were expected to do. But there was big changes in actual labeling practice. People also told us that they noticed the labels more and they said that they used them much more than they were previously. Like there was some labeling before. We had some big increases in noticing and using. But it's... we found this no change in calories purchased or calories consumed. Which leads to kind of interesting questions. Okay, so what were they doing with it when they were using it? And maybe some people were using it to help them make lower calorie choices, but other people were trying to optimize calories for money spent? We saw these very small changes in the mean calorie of items available that Mike's described in lots of detail. And then we also did some work kind of exploring with restaurants, people who worked in the restaurant chains and also people responsible for enforcement, kind of exploring their experiences with the policy. And one of the big conclusions from that was that local government were tasked with enforcement, but they weren't provided with any additional resources to make that happen. And for various reasons, it essentially didn't happen. And we've seen that with a number of different policies in the food space in the UK. That there's this kind of presumption of compliance. Most people are doing it all right. We're not doing it a hundred percent and that's probably because it's not being checked and there's no sanction for not following the letter of the law. One of the reasons that local authorities are not doing enforcement, apart from that they don't have resources or additional resources for it, is that they have lots of other things to do in the food space, and they see those things as like higher risk. And so more important to do. One of those things is inspecting for hygiene, making sure that the going out is not poisonous or adulterated or anything like that. And you can absolutely understand that. These things that might cause acute sickness, or even death in the case of allergies, are much more important for them to be keeping an eye on than labeling. One of the other things that emerged through the process of implementation, and during our evaluation, was a big concern from communities with experience of eating disorders around kind of a greater focus on calorie counting. And lots of people recounting their experience that they just find that very difficult to be facing in a space where they're maybe not trying to think about their eating disorder or health. And then they're suddenly confronted with it. And when we've gone back and looked at the literature, there's just not very much literature on the impact of calorie labeling on people with eating disorders. And so we're a little bit uncertain still about whether that is a problem, but it's certainly perceived to be a problem. And lots of people find the policy difficult for that reason because they know someone in their family or one of their friends with an eating disorder. And they're very alert to that potential harm. I think this is a really important point to raise that the law, the menu labeling, could have differential effects on different consumers. I'm not versed in this literature on the triggering effects of seeing menu labeling for people with disordered eating. But then I'm also thinking about a different group of consumers. Consumers who are already struggling with obesity, and whether or not this policy is more effective for those individuals versus folks who are not. In the work that you all did, did you have any sense of are there heterogeneous effects of the labeling? Did different consumers respond differentially to seeing the menu label? Not just, for example, individuals maybe with disordered eating? Mike - In this work, we mostly focused on compliance, customer responses in terms of consumption and purchases, changes in menus, and customers reporting whether or not they increase noticing and using. When we looked at the heterogeneous effects, some of these questions are what led us to propose a new project where we interviewed people and tried to understand their responses to calorie labeling. And there we get a lot of heterogenous groups. In those studies, and this work has not actually been published, but should be in the new year, we found that there's a wide range of different types of responses to the policy. For example, there may be some people who recently started going to the gym and maybe they're trying to actually bulk up. And so, they'll actually choose higher calorie items. Conversely, there may be people who have a fitness routine or a dieting lifestyle that involves calorie tracking. And they might be using an app in order to enter the calories into that. And those people who are interested in calorie counting, they really loved the policy. They really wanted the policy. And it gave them a sense of control over their diet. And they felt comfortable and were really worried that if there was evidence that it wouldn't work, that would be taken away. Then you have a whole different group of people who are living with eating disorders who don't want to interact with those numbers when they are eating out of home. They would rather eat socially and not have to think about those challenges. There's really vast diversity in terms of the responses to the policy. And that does present a challenge. And I think what it also does is cause us just to question what is the intended mechanism of action of this policy? Because when the policy was implemented, there's an idea of a relatively narrow set of effects. If customers don't understand the number of calories that are in their items, you just provide them with the calories that are in those items, they will then make better choices as rational actors. But we know that eating out of home is far more complex. It's social. There are issues related to value for money. So maybe people want to make sure they're purchasing food that hasn't been so reduced in portions that now they don't get the value for money when they eat out. There are all sorts of body image related challenges when people may eat out. We didn't find a lot of evidence of this in our particular sample, but also in some of our consultation with the public in developing the interview, there's concern about judgment from peers when eating out. So, it's a very sensitive topic. Some of the implications of that are we do probably need more communication strategies that can come alongside these policies and sort of explain the intended mechanism impact to the public. We can't expect to simply add numbers to items and then expect that people are going to make the exact choices that are sort of in the best interest of public health. And that sort of brings us on to some potential alternative mechanisms of impact and other modes of labeling, and those sorts of things. Mike, this has been really helpful because you've also hinted at some of the ways that this policy as implemented, could have been improved. And I wonder, do you have any other thoughts to add to how to make a policy like this have a bigger impact. Mike - Absolutely. One of the things that was really helpful when Jean laid out her framing of the policy was there's multiple potential mechanisms of action. One of those is the potential reformulation in menu change. We talked about those results. Another intended mechanism of action is through consumer choice. So, if items have fewer calories on average, then that could reduce ultimately calories consumed. Or if people make choices of lower calorie items, that could also be a way to reduce the overall calories consumed. And I would say this calorie labeling policy, it is a step because the calories were not previously available. People did not know what they were eating. And if you provide that, that fulfills the duty of transparency by businesses. When we spoke to people who worked in enforcement, they did support the policy simply on the basis of transparency because it's important for people to understand what they're consuming. And so that's sort of a generally acceptable principle. However, if we want to actually have stronger population health impact, then we do need to have stronger mechanisms of action. One of the ways that can reduce calories consumed by the consumers, so the sort of demand side, would be some of the interpretive labels. Jean mentioned them earlier. There's now a growing body of evidence of across, particularly in Latin America. I would say some of the strongest evidence began in Chile, but also in Mexico and in other Latin American countries where they've put warning labels on items in order to reduce their consumption. These are typically related to packaged foods is where most of the work has been done. But in order to reduce consumer demand, what it does is rather than expecting people to be sort of doing math problems on the fly, as they go around and make their choices, you're actually just letting them know, well, by the way, this is an item that's very high in calories or saturated fat, or sodium or sugars. Or some combination of those. What that does is you've already helped make that decision for the consumers. You've at least let them know this item has a high level of nutrients of concern. And you can take that away. Conversely, if you have an item that's 487 calories, do you really know what you're going to do with that information? So that's one way to have stronger impact. The other way that that type of policy can have stronger impact is it sets clear thresholds for those warnings. And so, when you have clear thresholds for warnings, you can have a stronger mechanism for reformulation. And what companies may want to do is they may not want to display those warning labels, maybe because it's embarrassing. It makes their candy or whatever the unhealthy food look bad. Sort of an eyesore, which is the point. And what they'll do is they can reformulate those nutrients to lower levels so that they no longer qualify for that regulation. And so there are ways to essentially strengthen both of those mechanisms of action. Whereas when it's simply on the basis of transparency, then what that does is leave all of the decision making and work on the consumer. Mike, this is great because I've worked with colleagues like Gabby Fretes and Sean Cash and others on some menu labeling out of Chile. And we're currently doing some work within the center on food nutrition labels to see how different consumers are responding. There's a lot more work to be done in this space. And, of course, our colleagues at UNC (University of North Carolina-Chapel Hill) have also been doing this work. So, this work is really important because it tells us how it can help consumers make different choices, and how it can affect how companies behave. My final question to the two of you is simply, what would you like policymakers to learn from this study? Or maybe not just this study alone, but this body of work. What should they take away? Jean - Well, I think there's lots of information out there on how to do food labeling well, and we can certainly learn from that. And Mike talks about the work from South America particularly where they're helping people identify the least healthy products. And they're also providing messaging around what you should do with that - like choose a product with fewer of these black symbols. But I think even if labeling is optimized, it's not really going to solve our problem of dietary related diseases. And I think I always want policymakers to know, and I think many of them do understand this, that there is no one magic solution and we need to be thinking about labeling as part of a strategy that addresses marketing in its entirety, right? Companies are using all sorts of strategies to encourage us to buy products. We need to be thinking of all sorts of strategies to support people to buy different products and to eat better. And I think that focuses on things like rebalancing price, supporting people to afford healthier food, focusing advertising and price promotions on healthier products. And I also think we need to be looking even further upstream though, right? That we need to be thinking about the incentives that are driving companies to make and sell less healthy products. Because I don't think that they particularly want to be selling less healthy products or causing lots of illness. It's those products are helping them achieve their aims of creating profit and growth for their shareholders. And I think we need to find creative ways to support companies to experiment with healthier products that either help them simultaneously achieve those demands of profit or growth. Or somehow allow them to step away from those demands either for a short period or for a longer period. I think that that requires us to kind of relook at how we do business in economics in our countries. Mike? Yes, I think that was a really thorough answer by Jean. So, I'll just add a couple points. I think most fundamentally what we need to think about when we're doing policy making to improve diet is we need to always think about are we helping to make the healthier choice the easier choice? And what that means is we're not implementing policies that merely provide information that then require individuals to do the rest of the work. We need to have a food environment that includes healthier options that are easily accessible, but also affordable. That's one thing that's come through in quite a lot of the work we've done. There are a lot of concerns about the high cost of food. If people feel like the healthier choices are also affordable choices, that's one of many ways to support the easier choice. And I really just want to reiterate what Jean said in terms of the economics of unhealthy food. In many ways, these large multinational corporations are from their perspective, doing right by their shareholders by producing a profitable product. Now there are debates on whether or not that's a good thing, of course. There's quite a lot of evidence for the negative health impacts of ultra-processed (UPF) products, and those are getting a lot more attention these days and that's a good thing. What we do need to think about is why is it that UPFs are so widely consumed. In many ways they are optimized to be over consumed. They're optimized to be highly profitable. Because the ingredients that are involved in their production means that they can add a lot of salt, sugar, and fat. And what that does is lead to overconsumption. We need to think about that there's something fundamentally broken about this incentive structure. That is incentivizing businesses to sell unhealthy food products with these food additives that lead to over consumption, obesity, and the associated comorbidities. And if we can start to make a little progress and think creatively about how could we incentivize a different incentive structure. One where actually it would be in a food business's best interest to be much more innovative and bolder and produce healthier products for everyone. That's something that I think we will have to contend with because if we are thinking that we are only going to be able to restrict our way out of this, then that's very difficult. Because people still need to have healthy alternatives, and so we can't merely think about restricting. We also have to think about how do we promote access to healthier foods. This is great insight. I appreciate the phrasing of making the healthy choice the easy choice, and I also heard a version of this making the healthy choice the affordable choice. But it also seems like we need to find ways to make the healthy choice the profitable choice as well. Bios: Jean Adams is a Professor of Dietary Public Health and leads the Population Health Interventions Programme at the University of Cambridge MRC Epidemiology Unit. Adams trained in medicine before completing a PhD on socio-economic inequalities in health. This was followed by an MRC Health of the Population fellowship and an NIHR Career Development Fellowship both exploring influences on health behaviours and socio-economic inequalities in these. During these fellowships Jean was appointed Lecturer, then Senior Lecturer, in Public Health at Newcastle University. Jean moved to Cambridge University to join the MRC Epidemiology Unit and CEDAR in 2014 where she helped establish the Dietary Public Health group. She became Programme Leader in the newly formed Population Health Interventions programme in 2020, and was appointed Professor of Dietary Public Health in 2022. Mike Essman is a Research Scientist at Duke University's World Food Policy Center. His background is in evaluating nutrition and food policies aimed at improving diets and preventing cardiometabolic diseases. His work employs both quantitative and qualitative methods to explore drivers of dietary behavior, particularly ultra-processed food consumption, across diverse environments and countries. Mike earned his PhD in Nutrition Epidemiology from the University of North Carolina at Chapel Hill, where his research focused on evaluating the impacts of a sugary beverage tax in South Africa. He completed MSc degrees in Medical Anthropology and Global Health Science at the University of Oxford through a fellowship. Prior to joining Duke, he conducted research at the MRC Epidemiology Unit at the University of Cambridge, where he evaluated the impacts of calorie labeling policies in England and led a study examining public perceptions of ultra-processed foods.  

In this episode, Amina Easat Daas and Claudia Radiven were in conversation with Peter Hopkins to discuss his work and most recent book, Everyday Islamophobia. The conversation ranged from UK counter-terror policy, to citizenship, the Far-Right, but largely on the mainstreaming of Islamophobia. Peter Hopkins is a Professor of Social Geography in the School of Geography, Politics and Sociology at Newcastle University. His interests centre upon issues of social inequality and justice with most of his research focusing upon the intersections of youth, migration and asylum, race and religion, and gender. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/new-books-network

In this episode, Amina Easat Daas and Claudia Radiven were in conversation with Peter Hopkins to discuss his work and most recent book, Everyday Islamophobia. The conversation ranged from UK counter-terror policy, to citizenship, the Far-Right, but largely on the mainstreaming of Islamophobia. Peter Hopkins is a Professor of Social Geography in the School of Geography, Politics and Sociology at Newcastle University. His interests centre upon issues of social inequality and justice with most of his research focusing upon the intersections of youth, migration and asylum, race and religion, and gender. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/islamic-studies

Checkpoint 300, the highly securitized border facility between occupied Bethlehem and Jerusalem, is a central feature of Israeli control of Palestinian land and life. An apparatus of turnstiles, overcrowded corridors, and invasive inspections, the checkpoint regulates the movement of hundreds of thousands of Palestinians, granting access to some while excluding most. Offering a nuanced exploration of space in Checkpoint 300: Colonial Space in Palestine (U Minnesota Press, 2025), Mark Griffiths reveals Checkpoint 300 as a stark symbol of Israeli colonialism that embodies larger systems of control and violence. Griffiths's sensitive and timely work highlights the myriad ways Palestinians are affected by Israel's spatial control—whether they travel through the checkpoint or not—demonstrating how colonial infrastructures of inequity extend far beyond their physical boundaries to shape daily life. Drawing on nearly a decade of fieldwork, Griffiths examines how colonial power infiltrates family dynamics, enforces gendered mobility restrictions, shapes local economies, and extends into the global exchange of capital and security technologies. He also underscores how Palestinians endure and resist under oppressive conditions and how indigenous forms of life and living are sustained, illuminating how colonial space is contested and countered, unmade and remade. Blending meticulous research with vivid human stories to show the lived realities of borders, power, and resistance in the West Bank, Checkpoint 300 portrays the checkpoint as an entry into the ways that colonial space is formed through security infrastructure that is both the product and producer of wider geographies of oppression, complicity, and control. Mark Griffiths is reader in political geography at Newcastle University. He is coeditor of Encountering Palestine: Un/making Spaces of Colonial Violence. Morteza Hajizadeh is a Ph.D. graduate in English from the University of Auckland in New Zealand. His research interests are Cultural Studies; Critical Theory; Environmental History; Medieval (Intellectual) History; Gothic Studies; 18th and 19th Century British Literature. YouTube channel. Twitter. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/new-books-network

Checkpoint 300, the highly securitized border facility between occupied Bethlehem and Jerusalem, is a central feature of Israeli control of Palestinian land and life. An apparatus of turnstiles, overcrowded corridors, and invasive inspections, the checkpoint regulates the movement of hundreds of thousands of Palestinians, granting access to some while excluding most. Offering a nuanced exploration of space in Checkpoint 300: Colonial Space in Palestine (U Minnesota Press, 2025), Mark Griffiths reveals Checkpoint 300 as a stark symbol of Israeli colonialism that embodies larger systems of control and violence. Griffiths's sensitive and timely work highlights the myriad ways Palestinians are affected by Israel's spatial control—whether they travel through the checkpoint or not—demonstrating how colonial infrastructures of inequity extend far beyond their physical boundaries to shape daily life. Drawing on nearly a decade of fieldwork, Griffiths examines how colonial power infiltrates family dynamics, enforces gendered mobility restrictions, shapes local economies, and extends into the global exchange of capital and security technologies. He also underscores how Palestinians endure and resist under oppressive conditions and how indigenous forms of life and living are sustained, illuminating how colonial space is contested and countered, unmade and remade. Blending meticulous research with vivid human stories to show the lived realities of borders, power, and resistance in the West Bank, Checkpoint 300 portrays the checkpoint as an entry into the ways that colonial space is formed through security infrastructure that is both the product and producer of wider geographies of oppression, complicity, and control. Mark Griffiths is reader in political geography at Newcastle University. He is coeditor of Encountering Palestine: Un/making Spaces of Colonial Violence. Morteza Hajizadeh is a Ph.D. graduate in English from the University of Auckland in New Zealand. His research interests are Cultural Studies; Critical Theory; Environmental History; Medieval (Intellectual) History; Gothic Studies; 18th and 19th Century British Literature. YouTube channel. Twitter. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/political-science

Checkpoint 300, the highly securitized border facility between occupied Bethlehem and Jerusalem, is a central feature of Israeli control of Palestinian land and life. An apparatus of turnstiles, overcrowded corridors, and invasive inspections, the checkpoint regulates the movement of hundreds of thousands of Palestinians, granting access to some while excluding most. Offering a nuanced exploration of space in Checkpoint 300: Colonial Space in Palestine (U Minnesota Press, 2025), Mark Griffiths reveals Checkpoint 300 as a stark symbol of Israeli colonialism that embodies larger systems of control and violence. Griffiths's sensitive and timely work highlights the myriad ways Palestinians are affected by Israel's spatial control—whether they travel through the checkpoint or not—demonstrating how colonial infrastructures of inequity extend far beyond their physical boundaries to shape daily life. Drawing on nearly a decade of fieldwork, Griffiths examines how colonial power infiltrates family dynamics, enforces gendered mobility restrictions, shapes local economies, and extends into the global exchange of capital and security technologies. He also underscores how Palestinians endure and resist under oppressive conditions and how indigenous forms of life and living are sustained, illuminating how colonial space is contested and countered, unmade and remade. Blending meticulous research with vivid human stories to show the lived realities of borders, power, and resistance in the West Bank, Checkpoint 300 portrays the checkpoint as an entry into the ways that colonial space is formed through security infrastructure that is both the product and producer of wider geographies of oppression, complicity, and control. Mark Griffiths is reader in political geography at Newcastle University. He is coeditor of Encountering Palestine: Un/making Spaces of Colonial Violence. Morteza Hajizadeh is a Ph.D. graduate in English from the University of Auckland in New Zealand. His research interests are Cultural Studies; Critical Theory; Environmental History; Medieval (Intellectual) History; Gothic Studies; 18th and 19th Century British Literature. YouTube channel. Twitter. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/middle-eastern-studies

Checkpoint 300, the highly securitized border facility between occupied Bethlehem and Jerusalem, is a central feature of Israeli control of Palestinian land and life. An apparatus of turnstiles, overcrowded corridors, and invasive inspections, the checkpoint regulates the movement of hundreds of thousands of Palestinians, granting access to some while excluding most. Offering a nuanced exploration of space in Checkpoint 300: Colonial Space in Palestine (U Minnesota Press, 2025), Mark Griffiths reveals Checkpoint 300 as a stark symbol of Israeli colonialism that embodies larger systems of control and violence. Griffiths's sensitive and timely work highlights the myriad ways Palestinians are affected by Israel's spatial control—whether they travel through the checkpoint or not—demonstrating how colonial infrastructures of inequity extend far beyond their physical boundaries to shape daily life. Drawing on nearly a decade of fieldwork, Griffiths examines how colonial power infiltrates family dynamics, enforces gendered mobility restrictions, shapes local economies, and extends into the global exchange of capital and security technologies. He also underscores how Palestinians endure and resist under oppressive conditions and how indigenous forms of life and living are sustained, illuminating how colonial space is contested and countered, unmade and remade. Blending meticulous research with vivid human stories to show the lived realities of borders, power, and resistance in the West Bank, Checkpoint 300 portrays the checkpoint as an entry into the ways that colonial space is formed through security infrastructure that is both the product and producer of wider geographies of oppression, complicity, and control. Mark Griffiths is reader in political geography at Newcastle University. He is coeditor of Encountering Palestine: Un/making Spaces of Colonial Violence. Morteza Hajizadeh is a Ph.D. graduate in English from the University of Auckland in New Zealand. His research interests are Cultural Studies; Critical Theory; Environmental History; Medieval (Intellectual) History; Gothic Studies; 18th and 19th Century British Literature. YouTube channel. Twitter. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/critical-theory

In this episode with Blake, we explore how we can use foot orthoses in various different case presentations in the lower limb. We discuss: Misconceptions about foot orthosesHow and when to use foot orthosesWhat conditions can respond well to foot orthosesDifferences between customised foot orthoses and off the shelf orthosesThis episode is closely tied to Blake's case study he did with us. With case studies, you can see how top clinicians manage real-world cases and apply their strategies to get better results with your patients.

Hala Shoman, a Palestinian PhD researcher in Sociology at Newcastle University, discusses her life in Gaza before 7 October 2023, the conditions under which Gazans have been living since, and the physical and political realities on the ground for Palestinians today. Shoman elaborates how Israel's violence since 2023 has left Palestinian society shattered, since the aggressions are so vast and profound that, unlike previous decades of aggressions that did not wipe out entire neighbourhoods and communities, the current genocide has left few able-bodied bodies alive who are can help their communities after each attack. Observing the harsh reality for Gazans today under the daily threat of murder, Shoman appraises how not only does every Palestinian personally know hundreds of people murdered over the past two years, but Israel's aggressions and control over every aspect of Palestinian life—their access to food, water and vaccines—have become so intensified that Palestinian infants are dying from the lack of drinking water necessary for baby formula. Confirming the direct links between Israel's violence and the increase in domestic violence in Gaza, Shoman recounts how the structural violence of colonialism and genocide has been reproduced: from the Israeli theatre of occupation and murder to the intimate space of family life within Palestinian communities. Expounding upon Israel's pathological desire to control Palestine, Shoman remarks that the very war criminals directing this genocide are the same individuals who are asked to lead Palestine in what is this latest farce of a “peace plan.” Shoman also elaborates her academic research that explores decolonial feminist frameworks and the concept of reprocide while also distinguishing between adapting to the horrors of this genocide and surviving it. Get full access to Savage Minds at savageminds.substack.com/subscribe

As the Government looks to appoint a new Freelance Champion for the creative industries we delve into the findings of the latest State of the Nations report from Creative PEC on Arts, Culture and Heritage workforce.Dr Mark Taylor will unveil the findings and plot the freelancer journey in the creative industries. A panel of guests including Yasmin Khan, Director for Individual Practitioners, Arts Council England, Philippa Childs, Deputy General Secretary, of the Broadcasting, Entertainment, Communications and Theatre Union, Amy Tarr, Head of Policy and Public Affairs, Creative UK, and Alexander Jacob, freelance television director, will explore how creative freelancers can be better supported and what the priorities should be for the new government champion. Chaired by Bernard Hay, Head of Policy, Creative PEC. Followed by Q&A and soft drinks reception.The new State of the Nations report, Who stays and who leaves?: Mapping arts, culture and heritage careers, will be released and available to download on the day.The Creative PEC is funded by the AHRC and led by Newcastle University with the RSA.Speakers:Speakers:Yasmin Khan, Director for Individual Practitioners, Arts Council EnglandPhilippa Childs, Head of BectuAmy Tarr, Associate Director, Policy & Research, Creative UKDr Mark Taylor, Research Lead for Arts, Culture and Heritage at Creative PEC, and Senior Lecturer in Quantitative Methods, University of SheffieldAlexander Jacob, Freelance television directorChair:Bernard Hay, Head of Policy, Creative PECDonate to the RSA: https://thersa.co/3ZyPOEaBecome an RSA Events sponsor: https://utm.guru/ueembFollow RSA on Instagram: https://www.instagram.com/thersaorg/Like RSA on Facebook: https://www.facebook.com/theRSAorg/Listen to RSA Events podcasts: https://bit.ly/35EyQYUJoin our Fellowship: https://www.thersa.org/fellowship/join

Host Jason Blitman talks to award-winning Irish writer Gráinne O'Hare about her debut novel, Thirst Trap. Conversation highlights include:❤️‍